207th OMICS Group Conference Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Scientific Tracks & Abstracts (Day 1)
GCC-2014 Page 29 Track 1 Day 1 September 15, 2014 1: Cancer - Basic and Applied Research
Session Chair Session Co-Chair Shinya Kimura Viji Shridhar Saga University, Japan Mayo Clinic, USA Session Introduction Title: The missing link between lipid droplets and autophagy in ovarian cancer Viji Shridhar, Mayo Clinic, USA Title: Medico-legal Compliance in India Arun Mishra, Legal MD Global Consulting Services Pvt Ltd, India Title: Shifting paradigms in surgical oncology -future of robotic surgery Chinna Babu Sunkavalli, APOLLO Hospitals, India Title: Safety, efficacy and survival rate comparison of Apceden® [dendritic cell (Dc) immunotherapy] with best supportive therapy in patients with refractory solid malignancies, on symptomatic treatment Suresh Attili, OMEGA Hospitals, India Title: Nasopharyngeal carcinoma – An 11 year study with respect to patient characteristics, clinical aspects and staging at presentation Shaqul Qamar Wani, Sher I Kashmir Institute of Medical Sciences (SKIMS), India Title: Living life to the fullest with “Cancer Rehabilitation” Shruti Velaskar, Tata Memorial Hospital, India Title: Molecular profiling of cancer cells – “Strategies for developing biomarkers for targeted therapies of cancer Pravin D Potdar, Jaslok Hospital & Research Centre, India Viji Shridhar et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
The missing link between lipid droplets and autophagy in ovarian cancer Viji Shridhar1, Debarshi Roy1, Susmita Mondal1, Xiaoping He1, Ashwani Khurana1, Chen Wang1, Ann Oberg1 and Thomas Dierks2 1Mayo Clinic, USA 2University of Bielefeld, Germany
t is increasingly being recognized that altered lipid metabolism is an early event in carcinogenesis and a central hallmark of Imany cancers. Under nutrient deprived conditions, excess free fatty acids are stored as triglycerides in lipid droplets (LD) to be used for energy. A second cellular response to starvation is autophagy, in which the cell digests its own components to provide nutrients. Microarray and Metabolomics profiling identified the lipid pathway as one the major pathways modulated by loss of HSulf-1 in OVCA. HSulf-1deficient cells (OV202 Sh1/sh2, OV2223 and Sulf-1 KO MEFs) possess high levels of lipid droplets (LD) that are absent in the HSulf-1 proficient isogenic cells (TOV21G and SKOV3). More importantly, TEM analysis showed that all HSulf-1 proficient cells displayed increased number of autophagic vesicles compared to isogenic HSulf-1 deficient cells. Pharmacological inhibition and ShRNA downregulation of cPLA2 activity, a protein involved in LD biogenesis resulted in decreasing the number of LDs and promoted autophagy in OV202 Sh1cells and elevated the autophagy inducing protein DAPK and autophagy related markers including LC3BII levels suggesting a novel cross-talk between LD biogenesis and autophagy in ovarian cancer cells. HS mimetic PG545, a tumor microenvironment targeting drug that mimics the action of HSulf-1, reduced LDs and promoted autophagy in Sh1 and Sh2 cells. Collectively, these results identify the critical role of HSulf-1, a major regulator of growth factor mediated signaling in the tumor microenvironment as the missing link in regulating both autophagy and LDs in OVCA.
Biography Viji Shridhar laboratory is focused on genetic, molecular and functional analysis on altered genes in ovarian cancer involved in chemoresistance and metastatic phenotype. He has a broad background in genetic, epigenetic, molecular and functional analysis of known and novel genes (identified using state of the art high throughput screening techniques) that may play important roles in the progression of ovarian and breast cancer. A major focus of my program is to understand the metabolic derangement in promoting ovarian carcinogenesis and therapeutically target pathways altered in ovarian cancer with novel therapeutics. He has previously shown that metformin, (an antidiabetic drug) treatment inhibits ovarian cancer cell growth both in vitro and in vivo and sensitizes cells to cisplatin induced cytotoxicity (hyperlinked). As PI or co-Investigator on several previous and currently funded NIH and Foundation-grants on the roles of HSulf-1 and HtrA1 in ovarian cancer, he has laid the groundwork for successfully completing the proposed research by developing resources and establishing productive collaborations. In addition, He has successfully administered the projects (e.g. staffing, research protections, budget), collaborated with other researchers, and produced several peer-reviewed publications from each project. He has a demonstrated record of successful and productive research projects in an area of high relevance and National interest. Over the past 15 years Viji Shridhar has mentored 22 postdoctoral fellows and 14 Clinical Fellows in my laboratory.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 31 Arun Mishra, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Medico-legal compliance in India Arun Mishra Legal MD Global Consulting Services Pvt Ltd, India
Biography Arun Mishra, a practicing advocate of High Court/ Supreme Court and a Medico-Legal Consultant, has completed his LL.M. (Crime) from Mumbai University. He also has to his credit three different graduations in Microbiology, Medicine and Law also different Post-Graduations in Medicine, Law, and in Yoga and other qualifications such as D.Pharma, D.M.L.T. and D.Yoga, all related to medicine. Having successfully handled 8000+ medico-legal cases in the last 8 years, he humbly attributes this to practical and combined knowledge of medicine and law. His ambition is to create awareness, unity and confidence amongst doctors. He has got his authority of writing 8 volumes of books on Law of Medicine. In the field of Medico-Legal, he is arguably the best among his peers in India. His success rate counts as on today is almost 100%.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 32 Chinna Babu Sunkavalli, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Shifting paradigms in surgical oncology -Future of robotic surgery Chinna Babu Sunkavalli APOLLO Hospitals, India
hanks to the rapid and continuing development of robotic technology, in the near future almost all kinds of endoscopic Tsurgery and thoracoscopic/ laparoscopic surgery will become performed by robotic surgery, not only for benign disease but also for malignant illnesses. New technology like Software integration for precise anatomy, 3D Animation, Artificial intelligence would compensate for the absence of tactile feedback . Having fewer personnel in the operating room and allowing doctors the ability to operate on a patient long-distance could lower the cost of health care in the long term. In addition to cost efficiency, robotic surgery has several other advantages over conventional surgery, including enhanced precision and reduced trauma to the patient. It is about time for Indian Hospitals to embrace Robotic Assisted Surgeries as we have at Apollo.
Biography Chinna Babu Sunkavalli, a renowned Surgical Oncologist is working on both the clinical research and in newer surgical techniques like robotics. At present he is consultant Robotic surgical oncologist at Apollo hospitals, Hyderabad.He graduated from prestigeous JJM medical College ,Davangere and continued to work in institutes like GCRI-Ahmedabad,TMH-Mumbai, at various positions. His clinical expertise can be exemplified by some of his achievements like first qualified and trained robotic surgeon of the AP and delivering highest satndards of pateint care. He had 34 publications in peer reviewed journals and is a sought after reviewer for various national and international journals such as Indian journal of surgery, Australian Asian Journal of Cancer. His accumen was recognised by international bodies and was honored with a felloship at Long Beach Cancer center in 2009. He was winner of many awards and to name a few, university topper and gold medallist during masters in surgery and superspecialization in surgical oncology. He has done GI fellowship in most prestigious cancer institute in the world- Memorial Sloan Kettering cancer centre, New York in the year 2009.He is professer in Surgical Oncology.He holds a professional degree in clinical research.His interest in laparoscopic Oncosurgery has made him to fous on robotics.He is trained in robotic surgery at Paris and Seoul in 2012.
He is also a Principal Investigator for more than a dozen international clinical trials and is the youngest investigator surgeon from India to be a part of the steering committee for Dr Reddys and a Key opinion leader. He is also a member of Ethics committee at BIBI cancer hospital and Medical Monitor for Phase I-IV oncology projects at ClinSync.
Besides being Minimally invasive Surgeon, His social work includes conducting many cancer awareness programmes and screening camps.His corporate social responsibilty part is done through an NGO-Grace cancer foundation which caters to the needy cancer patients.He is currently working as a Consultant Minimally invasive Surgical Oncologist and Robotic Surgeon, at APOLLO hospital, Hyderabad,India .Grace foundation is actively involved in public health research activities .It is focussed on spreading awareness, prevention and screening of cancer.Care, cure, compassion is his mantra for cancer victims.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 33 Suresh Attili et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Safety, efficacy and survival rate comparison of Apceden® [dendritic cell (Dc) immunotherapy] with best supportive therapy in patients with refractory solid malignancies, on symptomatic treatment Suresh Attili1, Bandana Sharan2, Ashok Kumar2, Chaitanya Kumar2 and Anjana Rizal2 1Clinical Research Pvt. Ltd., India 2Apac Biotech Pvt. Ltd., India
Objective: Owing to ethical considerations- a placebo control trial requires stringent necessary regulatory approvals, esp. in cancer treatment. As a result a number of trials are carried out without a placebo arm. Trials consisting immunotherapeutic products needs to be compared with a placebo to prove its efficacies of anticancer therapies in cancer patients. In order to establish the proof of concept, safety and efficacy of a dendritic cell based immunotherapy product –APCEDEN this study was carried out. Methods: The survival data obtained for APCEDEN® therapy was compared with the survival data collected for control subjects (no active systemic treatment). The control subjects (retrospective data) was matched with the geographical region, almost similar age, same gender and ECOG performance status, stage of the disease and for the subjects whose survival data is available. The demographic matched subjects with no active systemic treatment currently and their last received supportive therapy was considered for survival analysis. The retrospective data from the subject’s medical records with prior independent ethics committee’s approval was collected using data capture form. The data is collected from different centers across different geographical regions in India (Hyderabad, Nasik, and Bangalore). The clinical study co-coordinators were instructed to capture the data in the predesigned data capture form. The number of patients meeting the above criteria (n=85 for retrospective control data) and n=51 subjects from APCEDEN® was compared for survival analysis. The retrospective data collected receiving no active systemic treatment is referred as control group in this paper. Results: The survival analysis data between the treatment groups (APCEDEN® Vs control group) was analyzed twice. In survival analysis I, the total number of subjects N=51 who received the APCEDEN® was considered for analysis and in survival analysis II, about 13 subjects out of 51 subjects were excluded due to early drop outs without receiving complete therapy. In survival analysis I, the percent of censored values in the APCEDEN® treatment is 29.41% and no censored values for control group. The overall response rate in the APCEDEN® therapy is compared with the published data and fishers test results show that APCEDEN is not inferior to any of the immunotherapy product evaluated previously for solid malignant tumors. The median survival time for survival analysis I & II was found to be 173 and 211.5 days for APCEDEN treatment whereas 77 days for control group (95% CI). Hazard ratio was found to be 0.369 and 0.250 for survival analysis I & II respectively. Conclusions: The retrospective data collected and compared with APCEDEN suggests survival benefit of more than 100 days for APCEDEN therapy. The event free survival time of APCEDEN therapy was about 439 days in patients who showed objective response at first evaluation. Safety and efficacy data of APCEDEN was found to be comparable with already published data. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 34 Wani Shaqul Qamar et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Nasopharyngeal carcinoma: An 11 year study with respect to patient characteristics, clinical aspects and staging at presentation Wani Shaqul Qamar1, Talib Khan2, Lone M Maqbool1, Fir Afroz1 and Nazir A Khan1 1Sher-I-Kashmir Institute of Medical Sciences (SKIMS), India 2Government Medical College and Associated Hospitals, India
Background: Kashmir, having the pure ethnic, non-migrant population with unique lifestyle and dietary habits as a source of nitroso compounds which are implicated as causative agents for Nasopharyngeal Carcinoma (NPC). Objective: To determine the age and sex distribution, dwelling, smoking habits, clinical presentation and staging at the time of diagnosis/ presentation. Method: After approval from ethical committee, the total of 116 patients of NPC on follow up and those registered in the department of radiation oncology from January 2001 to December 2012 retrospectively with regard to their demographic parameters, smoking habits, clinical presentation and staging at the time of diagnosis were analyzed. The data collected were analyzed on SPSS software to interpret the results. Finding: The age ranged from 12–85 years with Mean ± SD and median age of 46.04±16.43 and 49 years respectively. The males: female ratio of 2.75:1. Most of the patients were from rural area 81.90% (N=95). Muslims were commonly affected 96.55 % (N=112). Smokers were 39.65 % (N=46), ex smokers 3.45% (N=4), snuff user 3.45 % (N=4), and non smokers were 53.44 % (N=62). With regard to clinical symptomatology, neck swelling was common presentation and was present in 73.27 % (N=85), followed by nasal obstruction, headache, epistaxis, hearing impairment, otalgia, nasal twang, dysphagia, intracranial extension, tinnitus, hoarseness of voice, proptosis, diplopia, impairment in vision, facial pain, nasal discharge, skull base involvement, cranial nerve involvement and decrease in eye movements. With regard to stage at disease presentation, stage I presentation was very low 1.74% (N=2), stage II was 33.91(N=39), stage III 30.44% (N=30.44), and stage IV 33.91% (N=39). Interpretation: Besides smoking, the lifestyle and dietary habits are unique for living in this cold northern part of the Indian subcontinent most likely to be the causative factors associated with NPC. Further studies are needed to establish the etiological insult.
Biography Wani Shaqul Qamar did her MBBS from Government Medical College Srinagar in year 2004 and completed her MD in Radiation Oncology from Sher-I-Kashmir Institute of Medical Sciences (SKIMS). She worked as Lecturer in the Department of Radiation Oncology, Government Medical College and Associated Hospitals, Srinagar. At present she is working as Assistant Professor in the Department of Radiation Oncology, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar. She has many publications in journals of international repute. She is interested in breast malignancies and head and neck cancers.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 35 Shruti M Velaskar, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Living life to the fullest with “Cancer Rehabilitation” Shruti M Velaskar Tata Memorial Hospital, India
ancer rehabilitation is a process that assists the patient and their family to obtain the best possible functional level within the Climitations of malignancy and its treatment. Despite the success in improvement of survival rates, many cancer survivors experience Physical, Psychosocial and Functional late effects due to the malignancy itself and/or the cancer treatment. Cancer rehabilitation need multidisciplinary approach and various rehabilitation branches like, Occupational therapy, Physiotherapy, Speech Therapist, Social Workers, Cancer Survivors and Volunteers play important role. The role of occupational therapy in oncology is “to facilitate and enable an individual patient to achieve maximum functional performance, in everyday living skills regardless of his or her life expectancy”. Common side effects of cancer or its treatment include pain, lymphdema, weakness, cognitive and perception difficulties, sensory problems, and changes in self-esteem and body image. Occupational therapy practitioners address these effects through intervention aimed at restoring function such as developing exercise programs to improve strength and mobility; lymphedema management, modifying activities such as energy conservative techniques, relaxation techniques, modifying environments such as the workplace, home, or community. Cancer rehabilitation is divided into various parts depending on the type of cancer like Head and neck cancer, breast cancer, palliative care etc. Rehabilitation following cancer is symptomatic and need to be modified depending on patients need and timely assessment of patient’s status. The whole approach is directed towards “Making a patient into person again the one who is not only wanted but accepted”.
Biography Shruti M Velaskar has passed her degree in Occupational Therapy from Seth G. S. Medical College and K. E. M. Hospital, Mumbai University. She is working since more than 15 years in this field and is attached to Tata Memorial Hospital since last 12 years as a Senior Occupational Therapist and is actively involved in cancer related clinical research and publication. She was awarded Fellowship for attending 2nd EORTC, QOL symposium held at Brussels, Belgium. She was awarded with “Best Scientific Paper” “Kamala V Nimbkar trophy for research and publication during 45thAIOTA Conference.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 36 Pravin D Potdar, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Molecular profiling of cancer cells: Strategies for developing biomarkers for targeted therapies of cancer Pravin D Potdar Jaslok Hospital & Research Centre, India
ancer is developed due to the exposure of cells to various carcinogens which cause DNA damage as well as from genetic Cpredisposition, where gene mutations are inherited from affected parents. Some forms of breast, colon and esophageal cancer are proved to be hereditary cancers and early detection of these cancers is very much essential. One of the main goals of cancer research is to identify molecules which are deregulated in the process of cancer development which can be used for early detection of cancer as well as to target cancer cells in vivo condition. These molecules are called biomarkers. The molecular biomarkers are mainly identified by using genomics, proteomics or imaging technologies such as PCR, Microarrays, FISH, etc. After completion of human genome project, the major challenge in oncology is to translate genetic information by advancement in several gene based technologies for diagnosis and management of various types of cancers. Recently, molecular profiling of tumor cells is also being used to determine specific types of malignancy. However, very few biomarkers are currently used as prognostic or predictive markers. Therefore, there is a great need to have a better understanding of new biomarkers of cancers and to translate them for use in early diagnosis and possible targeted therapies of cancers. This presentation will highlights most of the specific biomarkers which are presently used as a prognostic and predictive markers for breast, lung, colon, prostate, pancreatic and hematological cancers in human along with possible development in finding new biomarkers for better therapy.
Biography Pravin D Potdar has completed his PhD from Cancer Research Institute, Tata Memorial Centre Mumbai in year 1991. He has worked as a Senior Scientist for 20 years at Cancer Research Institute (Present ACTRECT), and did extensive research on establishing Biomarkers for early detection of lung, breast and oral cancers. He has more than 30 years of research experience in the field of cellular and molecular biology of cancer and other genetic disorders. He was a Fellow of National Institute of Health (NIH), USA and also worked as a faculty at M.D. Anderson Cancer Centre, Houston, Texas, USA for 3 years. He is a recipient of prestigious National Cancer Institute, NIH, USA and a Birla Smarak Kosh, Mumbai awards for his contribution in cancer research. Presently, he is heading Department of Molecular Medicine & Biology at Jaslok Hospital & Research Centre, Mumbai for last 9 years. He has successfully sequenced BRCA1 and BRCA2 genes and Wilson Diseases gene in his laboratory and discovered specific novel mutations in Indian population. He is associated with many organizations and hold positions in their committees. He was honored with position of a Secretary for Scientific Advisory and Ethics Committee of Jaslok hospital for 5 years. He is presently “Vice President” of “Molecular Pathology Association of India (MPAI), upcoming organization in the field of Molecular Pathology. He has more than 50 publications in national & international journals, appointed as a reviewer for many national and international journals and attended several conferences, workshops
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 37 207th OMICS Group Conference Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Scientific Tracks & Abstracts (Day 2)
GCC-2014 Page 47 Track 1 Day 2 September 16, 2014 1: Cancer - Basic and Applied Research
Session Chair Session Co-Chair Shinya Kimura Viji Shridhar Saga University, Japan Mayo Clinic, USA Session Introduction Title: Progression and control of tumorigenesis in f1 mice from the ethylnitrosourea exposed mothers involve mir-21 and pi3k/pten/akt pathway along with apoptotic events Krishna P Gupta, CSIR-Indian Institute of Toxicology Research, India Title: Application of Genomic Tools for Oncology diagnostics & prognosis: Cutting edge or cutting pocket! Bhaswar Maity, Imperial Life Sciences Pvt Ltd, India Title: Synergistic effect of ascorbate in napthoquinone induced cytotoxicity, ros/rns generation and inhibition of metastasis In vitro Sujay Gaikwad, Bhabha Atomic Research Centre, India Title: Tumor angiogenesis: A right target or a wrong choice? Rajesh N Gachche, Swami Ramanand Teerth Marathwada University, India Title: Controlled vestibular stimulation: Novel treatment for cancer pain: An update Kumar Sai Sailesh, Little Flower institute of Medical sciences and Research, India Title: Fish oil prevents bone metastasis of breast cancer and off-target toxicity of chemotherapies Chandi C Mandal, Central University of Rajasthan, India Title: Human breast cancer stem cells – Isolation and molecular characterization to understand mechanism of breast cancer Pravin D Potdar, Jaslok Hospital & Research Centre, India Title: Resveratrol modulates expression of abc transporters in non-small lung cancer cells: molecular docking and gene expression studies S Karthikeyan, Regional Medical Research Centre (ICMR), India Title: Advances in Breast Care – New Technologies like Vacuum assisted breast biopsies C P Copikker, Bard Medical, India Title: NKTR-214:A long-acting, engineered immunotherapy shows excellent therapeutic efficacy in multiple syngeneic mouse tumor modelsbothalone andin combination with checkpoint inhibition Murali Addepalli, Nektar, India Title: Design and verification of a next generation sequencing assay to accurately detect somatic DNA variants in FFPE samples from solid tumor tissue Nitin Udar, Illumina, USA Title: The impact of next generation sequencing technologies in clinical cancer research work and their application in cancer diagnostics and prognostics Ashok Gopinath, Illumina, India Title: Metal burden in cancer patients Praveen Kumar Saxena, Dr Saxena Centre for Progressive Medicine, India Title: Role of nutraceuticals in chemoprevention and cancer treatment N Dashrath Ram Reddy, Pro Young Internationals, India Title: Profiling of cell surface proteome and metabolome from an in vitro model system, using lc-ms technologies Ravi Krovidi, Agilent Technologies Pvt. Ltd, India Krishna P Gupta, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Progression and control of tumorigenesis in f1 mice from the ethylnitrosourea exposed mothers involve mir-21 and pi3k/pten/akt pathway along with apoptotic events Krishna P Gupta CSIR-Indian Institute of Toxicology Research, India
umors develop gradually as a result of a complex interaction of factors related to heredity, environment, lifestyle or diet. TThe understanding of the mechanisms could help in controlling the disease process and chemoprevention through the consumption of natural dietary compounds may reduce both morbidity and mortality from cancer. Epigenetic changes are correlated with tumor development showing aberrations in DNA methylation and histone modifications. Changes in DNA methylation and histone modification pattern and alteration in their modifying enzymes have been correlated with cancer development. To find the early changes, we evaluated the epigenetic events from early to late stage of the urethane induced lung tumor development in mouse model and tried to correlate the molecular events with the progression of tumor. Tumors did not appear after 1 or 4 weeks but well defined tumors appeared subsequently. The expression EZH2,of SUV39H1 and G9a is correlated with histone modification in terms of H3K9me2, H3K27me3 and H4K20 status and gene promoter interactions during the course of urethane induced lung tumorigenesis between 1-36 weeks. We addressed the hypothesis by examining the tumor development, DNA methylation and status of DNMTs, HDACs, MBDs and related genes along with micro RNA- 29b in the same samples. Development of tumors and molecular alterations were protected in presence of inositol hexaphosphate (IP6), a naturally occurring sugar phosphate. Study suggests that the epigenetic alterations before and during the tumor development could be used as possible targets of preventive strategies. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 49 Bhaswar Maity, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Application of Genomic Tools for Oncology diagnostics & prognosis ; cutting edge or cutting pocket! Bhaswar Maity Imperial Life Sciences, India
Biography Bhaswar Maity has done Phd in 2005on Forensic Genetics & Population Biology research. He has published 8 research papers in international peer reviewed journals. At present, he is National Sales Manager of ILS.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 50 Sujay Gaikwad et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Synergistic effect of ascorbate in napthoquinone induced cytotoxicity, ROS/RNS generation and inhibition of metastasis in vitro Sujay Gaikwad, Avik Chakraborty, Savita Kulkarni and M G R Rajan Bhabha Atomic Research Centre, India
uglone (5-hydroxy-1, 4-Napthoquinone), and structural analogue Plumbagin (5-hydroxy-2-methyl-1, 4-naphthoquinone) Jare natural product pigments. As per previous studies in our lab it was established that these compounds modulates inflammatory cytokines in RAW264.7 and THP-1 cell lines while significantly regressed C57BL/6-derived B16 melanoma. With an objective to investigate the mechanism of action of these napthoquinones in cytotoxicity and ROS generation in ARO (undifferentiated/ anaplastic thyroid cancer cell line); MTT and DCFDA fluorescent dye assays were performed respectively. Directional cell migration in vitro was studied by wound healing assay while colony formation in ARO cells in response to napthoquinones was studied by clonogenic assay. IC50 values of Plumbagin and Juglone in ARO cell line was found to be around 8-10 μM and 12-15 μM respectively. This cytotoxicity was restored by antioxidants NAC and GSH while increased by ascorbic acid. Cellular ROS/RNS was generated by Plumbagin and Juglone in ARO cell line. It was observed that nitric oxide (NO) inhibitors Aminoguanidine (AG) and NG-nitro-l-arginine methyl ester (L-NAME) in presence of Plumbagin (10 uM) and Juglone (15 μM) increases cellular ROS/RNS with respect to LNAME and AG controls. Ability of ARO cells to migrate and replenish the wound and form colony was significantly reduced with ascorbate and compounds together than with compound alone. ARO cells did not form colony above 2.5 μM concentration. Preliminary results shows ascorbate in presence of napthoquinone synergizes cytoxicity, wound healing and colony formation (metastasis markers) in ARO cell line. Antioxidants and NO inhibitors modulate direct action of napthoquinones in ARO. Role of Ascorbate in cellular pathways is under study.
Biography Sujay Gaikwad is working with Government of India, Department of Atomic Energy, and Bhabha Atomic Research Centre as Scientific Officer D.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 51 Rajesh N Gacche et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Tumor angiogenesis: A right target or a wrong choice? Rajesh N Gacche and Rohan J Meshram Swami Ramanand Teerth Marathwada University, India
ormation of new blood vessels (angiogenesis) has been proved to be a basic prerequisite for sustainable growth and Fproliferation of tumor. Several growth factors, cytokines, small peptides and enzymes support tumor growth either independently or in synergy. Decoding secretes of angiogenesis in physiological and pathological state has remained a subject of intense interest during the past three decades. Currently, the most established approach for arresting tumor angio¬genesis is blockade of the vascular endothelial growth factor (VEGF) pathway; however the clinical importance of this modality is still limited by several factors like adverse effects, toxicity, acquired drug resistance, non availability of valid biomarkers etc. Nevertheless angiogenesis being a normal physiological process imposes limitations in manoeuvring it as therapeutic target for tumor angiogenesis. The present paper offers an in depth discussions on the role of well-characterized angiogenic factors such as VEGF, basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), placenta growth factor (PLGF), hepatocyte growth factor/scatter factor (HGF/SF) and angiopoetins (ANGs) in regulating tumor angiogenesis. An attempt has been made to discuss tumor angiogenesis with a perspective of ‘a right target or a wrong choice’ along with the limitations and challenges of antiangiogenic therapy in the current state of the art. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 52 Kumar Sai Sailesh et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Controlled vestibular stimulation: Novel supplementary treatment for cancer pain- An update Kumar Sai Sailesh1, Archana R2 and Mukkadan J K2 1Little Flower Medical Research Centre (LFMRC), India 2Saveetha Medical College, India
ore than half of cancer patients have insufficient pain control, and about a quarter of them actually die in pain. Hence Mthere is a need for a novel method to relieve cancer pain, which is affordable and easily available to general population. Vestibular system is having extensive interactions with thalamus, hypothalamus, periaqueductal grey, parabrachial nucleus, cerebellum, nucleus tractus solitarius and raphe nuclei and modulates the activity of these areas to initiate pain modulatory responses. Controlled vestibular stimulation also modulates somato-sensory perception and attention and increases threshold for pain sensation. Controlled vestibular stimulation can be applied to relieve cancer pain and we suggest translational research in this area for patient care and treatment. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 53 Chandi C Mandal, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Fish oil prevents bone metastasis of breast cancer and off-target toxicity of chemotherapies Chandi C Mandal Central University of Rajasthan, India
Objective: Nearly 85% of breast cancer patients are dying due to bone metastasis of breast cancer. Beside this, off-target toxicity of chemotherapeutic drugs is a major constraint in treatment of cancer patients. Non-toxic omega-3 fatty acids DHA and EPA, active components of fish oil, shows several beneficiary effects to our health including anti-tumorigenic activity. This study has investigated to know whether fish oil prevents systemic toxicity of chemotherapeutic drugs, and breast cancer bone metastasis. Methods: To test bone metastasis, human breast cancer MDA-MB-231 cells were administered to left cardiac ventricles of nude mice by intra cardiac injection and to test side effects of chemotherapeutic drugs, these drugs were orally fed to cat fishes, followed by fish oil and PBS treatment for experimental and control groups of animals. Western blotting and quantitative RT-PCR were performed for the detection of CD44 and miR-21. Biochemical assays were performed to test liver and kidney functions. Results: Metastasis model experiments showed a significant inhibition of breast cancer osteolytic bone metastasis in hind limb of fish oil-treated mice as compared to control mice. DHA and EPA, active components of fish oil, inhibit breast cancer cells migration by blocking cancer stem cell marker CD44. Levels of osteoclastogenic colony stimulating factor-1 (CSF-1) and oncomiR miR-21 were found to be remarkably high in metastatic breast cancer cells as compared to non- metastatic breast cancer cells. Treatment of cat fishes with doxorubicin/cisplatin showed severe skin damages which were prevented by omega-3 fatty acids treatment, indicating a preventive role of omega-3 fatty acids in chemotherapeutic drug-induced toxicity. Chemotherapeutic drugs-elevated SGPT, ALP and MMPs activity were diminished by fish oil treatment. Moreover, fish oil treatment reverses chemotherapeutic drugs-mediated inhibition of SOD activity to shut down ROS level and MMPs activity. Conclusions: The study for the first time unravels that fish oil inhibits breast cancer bone metastasis by targeting CD44, miR-21 and CSF-1 in nude mice model and omega-3 fatty acids prevent chemotherapeutic drug-driven systemic toxicity presumably by reducing ROS level.
Significance: This study recommends that omega-3 fatty acids may possibly be used in combination with chemotherapeutic drugs for treatment of different cancers to lessen chemotherapeutic drugs-associated systemic toxicity and to augment anti- metastasis activity of breast cancer. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 54 Pravin D Potdar, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Human breast cancer stem cells: Isolation and molecular characterization to understand mechanism of breast cancer Pravin D Potdar Jaslok Hospital & Research Centre, India
reast cancer remains a leading cause of morbidity and mortality in Indian women. Last 6 years, our lab is working on Bstudying molecular markers for early detection of breast cancer and established BRCA1 & BRCA2 testing. We have reported novel founder mutation in BRCA2 gene in Indian women. As identification of potential breast cancer stem cells is most important in a view of targeting these cells, we thought of isolating & molecular characterizing these cell types from metastatic breast cancer tumor. Our Immunofluorescence studies have shown that these cells are large cells with enlarged nucleus and nucleolus with granulated cytoplasm. These cells highly expressed nine breast cancer specific genes indicating their cancer phenotypes. It was also observed that these Breast Cancer Initiated cells transferred their cancer phenotype to neighboring normal cells to make them transform. Therefore targeting of these cells by specific biomarkers is a major task in curing breast cancer at advance stage of cancer. We have also looked at additional pluripotency markers in these cell types and interestingly, it was found that SOX2 & OCT4 genes were completely down regulated in these cancer stem cells. We have therefore proposed further hypothesis to introduce these genes in these cancer stem cells to developed iPSC cell line. These iPSC cells may be useful for restricting and killing of breast cancer tumor cells from their respective patient as a breast cancer therapy in near future. This presentation will highlight innovative approach for future diagnosis & therapies of breast cancer.
Biography Pravin D Potdar has completed his PhD from Cancer Research Institute, Tata Memorial Centre Mumbai in year 1991. He has worked as a Senior Scientist for 20 years at Cancer Research Institute (Present ACTRECT), and did extensive research on establishing Biomarkers for early detection of lung, breast and oral cancers. He has more than 30 years of research experience in the field of cellular and molecular biology of cancer and other genetic disorders. He was a Fellow of National Institute of Health (NIH), USA and also worked as a faculty at M.D. Anderson Cancer Centre, Houston, Texas, USA for 3 years. He is a recipient of prestigious National Cancer Institute, NIH, USA and a Birla Smarak Kosh, Mumbai awards for his contribution in cancer research. Presently, he is heading Department of Molecular Medicine & Biology at Jaslok Hospital & Research Centre, Mumbai for last 9 years. He has successfully sequenced BRCA1 and BRCA2 genes and Wilson Diseases gene in his laboratory and discovered specific novel mutations in Indian population. He is associated with many organizations and hold positions in their committees. He was honored with position of a Secretary for Scientific Advisory and Ethics Committee of Jaslok hospital for 5 years. He is presently “Vice President” of “Molecular Pathology Association of India (MPAI), upcoming organization in the field of Molecular Pathology. He has more than 50 publications in national & international journals, appointed as a reviewer for many national and international journals and attended several conferences, workshops and seminars all over India and abroad. His name is also included in Marquis Who's Who in World” Book 2012.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 55 S Karthikeyan et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Resveratrol modulates expression of ABC transporters in non-small lung cancer cells: Molecular docking and gene expression studies S Karthikeyan and S L Hoti Regional Medical Research Centre (ICMR), India
ultidrug resistance (MDR) is one of the most common causes of relapse in cancer chemotherapy. Inhibition of ABC Mtransporters to reverse MDR is a promising approach to enhance the efficacy of cancer chemotherapy. It was investigated the effect of Resveratrol (RSV) on the membrane transport function and the expression of proteins involved in the multidrug resistance in NCI-H460 cells. The membrane transport function was determined using Rhodamine 123 staining. The mRNA expression level of MDR1, LRP, MRP2, ABCC1, ABCC2 and ABCC3 genes were detected by qRT-PCR and P-glycoprotein (P-gp) expression was detected by western blot analysis. In silico docking studies revealed that RSV possesses greater binding affinity with TMD region of P-gp. In this study, RSV pretreatment significantly enhanced Paclitaxel (PTX) antiproliferative effect in NCI-H460 cells. The Rhodamine 123 drug efflux studies revealed that there was a significant transport function inhibition by RSV treatment and moderate transport function inhibition by PTX. Further, RSV treatment significantly decreased the mRNA expression levels of various ABC transporters genes. Furthermore, expression of P-gp was found to be down regulated during RSV treatment. It was also found that this enhanced anticancer efficacy of RSV was associated with PTX-induced cell arrest in the G2/M phase of cell cycle. Interestingly, significantly enhanced antiproliferative effect, transport function inhibition and down regulation of ABC transporters in RSV-PTX combination group was observed. This might be due to additive or synergistic effect of RSV with PTX in NCI-H460 cells. Thus, the present findings illustrate the modulatory role of RSV on PTX sensitization in resistant NCI-H460 cells.
Biography S Karthikeyan has completed his PhD in Biochemistry from Annamalai University, Chidambaram and is currently working as ICMR-Post-Doctoral Fellow at Regional Medical Research Centre, Belgaum, India. He has published all his research findings in reputed journals and has served as a resource person in two National level workshops. He is currently looking at the effect of phytochemicals on chemosensitization in cancer cells and is his prime research interest. He is actively involved in the identification of MDR modulators from natural sources and will pursue the long term goal of development of effective chemomodifier to be applicable in health care and clinical oncology.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 56 C P Copikker, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Advances in Breast Care – New Technologies like Vacuum assisted breast biopsies C P Copikker Bard Medical, India
rought integrated cancer care to Pune through planning and establishment of the cancer Facility at Inlaks and Budhrani BHospital. This was the first integrated facility outside the Tata Memorial hospital in Maharashtra at that time and offered Bone Marrow transplant facility Helped set up the cancer facility at two more centers in Pune - at Ruby Hall and at Jahangir, established the first Mammography center in Pune and a comprehensive Breast Unit which did the first Breast conserving surgery way back in 1993 – this patient incidentally is still alive. Brought in and pioneered a variety of surgical procedures in Pune and in the country. First to introduce procedures like breast conserving surgery, Oncoplastic surgery, sentinel node biopsy, VABB procedure in the country. Established the first and only comprehensive breast screening center with Automated Breast Ultrasound in the city at Orchids breast specialty center. First to set up Oncolplastic breast surgery facilities in Pune and one of the first and few in the country. Combining cancer surgery with cosmetic surgery for breast cancer patients.
Biography C P Copikker recognized as a trainer for breast reconstructive surgery in India. Have trained several surgeons from India and Abroad. Established the International School of Oncoplastic Surgery In Pune and Held the First Master Class in Oncoplastic Surgery in India in affiliation with the Association of Breast surgeons UK and the East Anglia University. Through this school wish to spread the awareness and training in Oncoplastic surgery in India. Established along with social workers and Cancer survivors the Prashanti Cancer Care Mission in1995 to take care of every need of the cancer patients. The mission serves over 3000 patients today.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 57 Murali Addepalli et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
NKTR-214: A long-acting, engineered immunotherapy shows excellent therapeutic efficacy in multiple syngeneic mouse tumor models both alone and in combination with checkpoint inhibition Murali Addepalli1, Rupesh Kanhare1, Priyam Jha1, Vennam Srinivas1, Steve Lee2, Paul Sims2, Hoch Ute2, Charych Deborah2 and Seema Kantak2 1Nektar Therapeutics India (Pvt.) Ltd., India 2Nektar Therapeutics, USA
ytokine-based immunotherapy has been successful for the treatment of cancer with potential for durable responses in Ca variety of indications. One approach for stimulating the immune system is to target the heterotrimeric interleukin 2 receptor; IL 2R.NKTR-214 is a uniquely transformed IL-2 that is shown to be differentiated from the parent IL-2 by its in vitro and in vivo activities. NKTR-214 uses polymer technology to alter receptor subunit selectivity to favor expansion of CD8+ memory effector T cells (CD8T) over CD4+ regulatory T cells (Treg) in the tumor. In addition, polymer technology improves exposure and enhances tumor localization, thereby resulting in significantly improved efficacy, modulated toxicity and flexible dosing regimens in the tested models. These unique properties of NKTR-214 enable substantial efficacy as a single agent in an aggressive mouse melanoma model and in other syngeneic tumor models. In addition, NKTR-214 shows synergy in combination with the checkpoint inhibitor, anti-CTLA4 antibody, in mouse breast and colon tumors. NKTR-214 is a highly differentiated cytokine with a new mechanism of action that may provide new options for cancer immunotherapy. IND- enabling studies are ongoing.
Biography Murali Addepalli is responsible for leading and managing Pharmacology group at Nektar India in alignment with global discovery teams leading to strengthen of product pipeline. Dr. Addepalli has joined Nektar in 2010 and brings with him more than 14 years of experience in various therapeutic areas which include oncology, pain and inflammation. Prior to joining Nektar he was associated with leading pharmaceutical organizations such as Reliance Life Sciences and Biocon Bristol Meyers. Dr. Addepalli was a founder director of IBC (Innovative Biotech Consultants Pvt. Ltd., Singapore).He is member of various international bodies aimed at cancer prevention and cure. Dr. Addepalli received his M.Sc. from University of Hyderabad (Hyderabad), and Ph.D from University of Nagasaki (Japan). Also he was awarded visiting Fellow at NIDDK, NIH (Bethesda, USA) in the field of centrosome biology. Dr. Addepalli has numerous patents (USA, Europe and India) and publications to his credit. Presented many abstracts at various international scientific meetings and received honors to his distinguished career.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 58 Nitin Udar, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Design and verification of a next generation sequencing assay to accurately detect somatic DNA variants in FFPE samples from solid tumor tissue Nitin Udar Illumina, USA
esigning a next generation sequencing (NGS) DNA sequencing assay that can detect low frequency variant is a highly Ddesired goal for therapy selection in cancer especially for the detection of actionable targets that have clinical utility. Formalin Fixed Paraffin Embedded (FFPE) tissue is the most common sample type for solid tumor histopathology. However, because the fixation process fragments DNA and damages it at varying frequencies, downstream processes can potentially misclassify modified bases and generate artifacts. We have developed a protocol that addresses both of these issues in a multiplex assay that involves deep sequencing using NGS of targets implicated in lung, gastric, colon, melanoma and ovarian cancers. A total of 200 samples were tested for 26 genes and sequencing on the MiSeq platform. The qPCR based DNA quality test, was an accurate determinant of DNA amplifiability and yielded a 99% sample success rate. A sensitivity of <5% MAF was achieved by sequencing at a minimum depth of 1,000X for all targets (average depth 20,000X). In order to differentiate true low frequency variants from fixation and other artifacts, our novel approach investigates each of the two DNA strands independently. The information was bioinformatically combined to distinguish true variants from artifacts. Testing of the FFPE samples with a 5% MAF cut off using the two strand approach reduced the potential false positive rate by ~ 40% when compared to information from only one strand of DNA. This assay, efficiently and accurately detected low frequency variants by NGS in DNA extracted from FFPE tissues.
Biography Nitin Udar has completed his PhD from Maharaja Sayajirao University, Vadodara, India followed by a Fellowship in Molecular Diagnostics and Faculty at the University of California Los Angeles, USA. He is currently a Scientific Manager focused on Oncology within the In vitro Diagnostics (IVD) division at Illumina, San Diego, USA. He has published more than 50 papers in reputed journals as well as several book chapters.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 59 Ashok Gopinath, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
The impact of next generation sequencing technologies in clinical cancer research work and their application in cancer diagnostics and prognostics Ashok Gopinath Illumina, India
he rapidly evolving field of genomics and the giant strides being made in genomic technology are making significant Timpact to applied markets. The large volume of data on cancer genomes is increasing our knowledge base to try and interpret the causes and possibly reveal novel targets that could lead to the cure for this dreaded disease. Clinical research efforts have led to discoveries that are currently being leveraged to construct clinical diagnostics. Already the construction of clinically relevant biomarker panels (companion diagnostics) is promising to revolutionize the diagnostic and prognostic value for different therapeutic regimens. This talk will briefly address the current state of clinical genomics, more specifically cancer genomics and showcase Illumina’s panel based clinical solutions and how they may be leveraged to try and provide clues to the directions clinical therapeutics will progress in.
Biography Ashok Gopinath has a PhD from the Dept. of Biochemistry at the Indian Institute of Science (IISc) in Bangalore. He moved to Cornell University in Ithaca New York, for Postdoctoral research work in axon guidance. Since then, he re-committed himself to applied research work in the fundamental areas of diabetes and oncology in the industry most recently at Sanofi. He established many public private partnerships in the field of oncology and diabetes while at Sanofi. In Illumina now as the Head of Applied Genomics in India, he aspires to discover and impact evolving frontiers in healthcare and life sciences using genomics.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 60 Praveen Kumar Saxena, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Metal burden in cancer patients Praveen Kumar Saxena Dr Saxena Centre for Progressive Medicine, India
he cancer prevalence in the Hyderabad is much higher than the national average cancer prevalence in India. The Tparticipants in the present study were 8 healthy individuals and 9 cancer patients all living in and around Hyderabad, with the healthy people being selected from the same household as the cancer patients. High concentrations of several potentially toxic elements were found in hair samples from people living in Hyderabad. Compared to standard reference ranges, the metals in excess in both the control and patient groups were aluminum (Al), barium (Ba), manganese (Mn), strontium (Sr) and uranium (U). The most significant findings were high lead (Pb), U and Ba concentrations. The maximum values for Ba, Mn, Pb and U were found in hair from breast cancer patients. The mean concentration of U in hair from the breast cancer patients was 0.63 μg U/g, which is more than double the value found in the control group and over six times higher than the reference range of 0.1 μg U/g. Water, soil, and phosphate fertilizers all seem to play a potential role, causing an increased metal burden in these group. The present study indicates that metals, and especially U, may be a factor in the development of breast cancer. The metal burden of multiple toxic metals as found in all groups can be reduced with precautionary measures, including a change in agricultural approaches and detoxification treatments for those already burdened. A reduction in total metal burden, however achieved, can only improve health. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 61 N Dasharathram Reddy, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Role of nutraceuticals in chemoprevention and cancer treatment N Dasharathram Reddy Pro Young International, India
y understanding the concept of oxygen free radicals creating oxidative stress in the development of carcinogenesis offers Bus a host of new possibilities of how to prevent cancer by discovering the wonderful results of a whole new approach of true preventive medicine by practicing a consistent exercise program, eating a healthy organic diet, and consuming various high quality nutritional supplements in the optimal dosage to super charge the natural antioxidant defense system to repair any cancer cell is the cellular nutrition leading to vibrant health.
Biography N Dasharathram Reddy completed MBBS in 1973 and MS (Gen. Surgery) in 1977 from O.U. Board certified by American Board Anesthesiology, ABA-Critical care medicine; ABA – Pain Management and Diplomat of American Board of Pain Medicine. He had been associated with many healthcare facilities in the US like Martin Luther King Jr. Hospital, Los Angeles; Good Samaritan Hospital and Medical Centre, Wright State University, Dayton, Ohio and Medical Director of Pain Management Centre of Dayton, Ohio. He is senior consultant in pain management, palliative care, nutritional & regenerative medicine. He is the Vice chairman and president of Pro Young International & Medical Director of Total Wellness.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 62 Ravi K Krovidi et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Profiling of cell surface proteome and metabolome from an In vitro model system, using LC-MS technologies Ravi K Krovidi1, Arun Kumar Padmanaban1, Lynette Lincoln1, Syed Salman Lateef1 and Leo Bonilla2 1Agilent Technologies India Pvt. Ltd., India 2Agilent Technologies, USA
Introduction: Cell surface membrane proteins play a predominant role in cellular signaling processes. Membrane specific receptor proteins serve as cellular markers, prime drug targets to several pharmaceutical agents. Receptor proteins have been targeted to decipher the molecular mechanisms for several cancers e.g.; breast, epidermoid and lung cancers. Immuno- phenotyping assays provide a comprehensive understanding of cell surface markers, but limited by the availability of sp. antibodies. We adopted the chemical biotinylation enrichment methodology coupled with LC-MS technologies to analyze the spatio-temporal changes of protein expression along with secreted metabolome signatures from EGF induced epidermoid carcinoma cell lines-A431. In our current study we evaluate the global qualitative profiling of cell surface proteins and secreted metabolites. Methods: A431 cells were cultured in DMEM medium as described. Chemical biotinylation was carried out following the recommendations from Pierce chemicals. Briefly, the cells were grown to 90% confluence and washed with ice-cold PBS and Sulfo-NHS-SS-Biotin solution was added at a final concentration of 0.25 mg/ml for 30 minutes with gentle agitation. The adherent monolayer was washed, scrapped into PBS solution and centrifuged to collect the cell pellet, followed by lysing under denaturing condition, biotinylated proteins are then affinity purified using NeutrAvidin column with DTT denaturation. The eluted protein was digested with Trypsin/Lys-C mix, resulting peptides were analyzed using a microfluidic-based nanoflow LC coupled to Q-TOF MS. Data reprocessing was performed using software for protein database search for protein analysis. Preliminary data: Employing the chemical enrichment strategy with NHS-SS-Biotin probe, target cell surface proteins were enriched from A-431, epidermoid carcinoma cell lines. Enriched proteins were subjected to proteolytic digestion using Trypsin/Lys-C mix. The resulting peptide mixtures were desalted and subjected to a medium to long 45 min linear gradient separations of acetonitrile (ACN) in 0.1% formic acid delivered at 300 nL/min over a C18 reverse phase LC system using a microfluidic device. LC-MS/MS data was acquired in both centroid and profile modes. Acquired spectra were then searched with Spectrum Mill search engine against the Homo sapiens, Uniprot FASTA protein database. A mass accuracy of +/- 50 ppm was used for precursor ions and 0.6 Da for product ions. Higher sensitivity levels of peptide detection with dual-stage ion funnel technology have resulted in the identification of several cell surface membrane proteins including extra cellular matrix proteins, moderately abundant proteins including pancreatic marker protein, Plectin-1 along with F-Box Leucine rich repeat protein-2, Beta Actin, PGK-2, Annexin-2, etc. Our preliminary results demonstrate the ability of the chemical affinity, LC-MS enrichment strategy, to identify the cell surface membrane proteins. Cell surface proteome complemented with secreted metabolome from EGF induced epidermoid carcinoma cell lines would provide a deeper understanding of the spatio-temporal events of the cellular machinery and an insight into potential metabolite signatures upon drug treatment. Metabolome profiling and data anlaysis is currently underway. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 63 207th OMICS Group Conference Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Scientific Tracks & Abstracts (Day 3)
GCC-2014 Page 65 Track 2 Day 3 September 17, 2014 2: Cancer Diagnostics and Therapy
Session Chair Session Co-Chair Gayatri Gogoi Sushmita Pathy Assam Medical College & Hospital, India All India Institute of Medical Sciences, India Session Introduction Title: Evaluation of hormonal receptor status and its correlation with proliferative marker Ki67 in breast cancer Gayatri Gogoi, Assam Medical College & Hospital, India Title: Membrane fusion mediated cytosolic drug delivery through scFv targeted Sendai viral envelopes Mukesh Kumar, All India Institute of Medical Sciences, India Title: Validation and translation of EORTC, CIPN20 module to evaluate chemotherapy induced neuropathy in patients treated with chemotoxic medicines Shruti Velaskar, Tata Memorial Hospital, India Title: Role of radiation in multidisciplinary management of rectal cancer Sushmita Pathy, All India Institute of Medical Sciences, India Title: Microwave Imaging for breast cancer screening -A potential approach Bhaskar Naik S, Indian Institute of Technology, India Gayatri Gogoi et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Evaluation of hormonal receptor status and its correlation with proliferative marker Ki67 in breast cancer Gayatri Gogoi, Manash P Baruah, M Borgohain and S A Fazal Assam Medical College, India
Background: Breast cancer is the leading cause of death in women. Hormonal receptor status is the most important prognostic and predictive marker for breast cancer. It has been used in management of breast cancer since 1970s as an indicator of endocrine responsiveness and prognostic factor for recurrences. Again complete study by breast cancer panel namely Estrogen Receptor, Progesterone Receptor, Her2/neu classify breast tumours into 5 molecular subtypes. Among those two types of hormonal receptor positive breast cancers are derived Luminal A, is defined by as only Estrogen receptor [ER] and Progesterone Receptor [PR] positive by tumour cells and Luminal B, is defined by ER/PR as well as Her2/neu positive by tumour cells. Markers of proliferation, and specifically Ki-67-labelling index, are also considered important for the determination of prognosis. Aim and Objective: To evaluate hormonal receptor status in invasive breast carcinoma and study the proliferative behavior of both Luminal A and B were examined by Ki67 expression. Setting and Design: A prospective analysis of 112 breast patients was undertaken to study the histomorphological features followed by immunohistochemical study in Department of Pathology. The mastectomy specimens were received from Department of Surgery and private hospitals of surrounding area. Material and Methods: Histological confirmation of breast cancer, special features, histological Bloom Richardson Grading [BRG] was done. All surgically rejected lymph nodes were examined for presence of secondary and ascertained early vs advanced status of breast cancer.Immunohistochemistry profile for ER PR, Her2neu, Ki67 were done on formalin-fixed paraffin embedded tissue blocks, using ER antibody clone and PR antibody clone using standard procedure. Ethical clearance was received before start of the study from Institutional Ethics committee for Human research of study institution. Results: The average age of breast cancer presentation in this study was 44.6 years. Hormonal receptors were positive only in 47% of breast cancer cases. Out of that Luminal A was 31% and Luminal B was 16%. The Ki67 expression pattern showed a statistically significant correlation with Luminal A as low proliferation whereas Luminal B showed a higher proliferation pattern. Conclusion: Hormonal receptor status was taken as good prognostic factor but it is not an independent status. The co- expression of Her2neu with HR receptor was found to have more aggressive behavior. Proliferation pattern of Ki67 Luminal A and Luminal B indicates different biologic entity. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 67 Mukesh Kumar et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Membrane fusion mediated targeted cytosolic drug delivery through scFv engineered Sendai viral envelopes Mukesh t, Prashant Mani2, Pooja Pratheesh1,4, Sunandini Chandra2, Meghala Jeyakkodi2, Parthaprasad Chattopadhyay1, Debi P Sarkar2 and Subrata Sinha1,3 1All India Institute of Medical Sciences, India 2University of Delhi, India 3National Brain Research Center, India 4Mahatama Gandhi Medical College and Hospital, India
Antibody targeted cytoplasmic delivery of drugs is difficult to achieve as antigen-antibody interaction results in the payload being directed to the endosomal compartment. However, Sendai viral envelopes can bring about cytoplasmic delivery due to F-protein mediated membrane fusion. In this study, a recombinant scFv directed to the onco-fetal antigen, the Placental Isozyme of Alkaline Phosphatase (PAP) was generated and fused with the trans-membrane and part of the cytoplasmic domain of the Sendai F protein (FTMC). Reconstituted virosomes, having both the fusion protein as well as the native F-protein were able to specifically bind and deliver drugs to PAP expressing cells. About 75% of the delivery was cytoplasmic in nature. Hence, this immuno-virosome, which is devoid of the comparatively more toxic HN protein, has the novel ability to combine specific antibody mediated targeting with cytoplasmic delivery. The scFv ensured specific binding to PAP expressing cells, without cross reacting with the other isozymes of alkaline phosphatase. The advantages of cytoplasmic delivery would include reduced degradation and lowered immunogenicity of the payload and carrier. The ubiquitous expression of PAP on a variety of cancers like seminoma, choriocarcinoma, cervical and breast cancers also suggests its potential usefulness in a number of malignancies.
Biography Mukesh Kumar has completed his Ph.D. in Biochemistry from All India Institute of Medical Sciences, New Delhi in 2012. During his Ph.D., he worked on the development of targeted therapeutic modality against tumors expressing placental isozyme of alkaline phosphatase (PAP) on their surface. He has used human phage display antibody library for selection of the targeting molecule (scFv) and incorporated this scFv in F-virosome (reconstituted envelope of Sendai viral membrane devoid of HN protein) to deliver the cargo directly in the cytosol through membrane fusion mediated process. Such modality can have better cytotoxic effect since they escape the acidic environment of endocytotic pathway, an intrinsic cellular pathway of antibody-antigen complex internalization, and minimize the degradation of drug or macromolecules. At present, he is working as Research Associate at National Brain Research Center, Manesar, Haryana which has been awarded by Indian Council of Medical Research (ICMR) to study the effect of tumor microenvironment on PAP expression in a sub-population of tumor cells i.e. cancer stem cells which is responsible for both initiation and chemoresistance of tumors. Targeting of cancer cells along with cancer stem cells would be more effective for tumor therapy.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 68 Shruti M Velaskar et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Validation and translation of EORTC, CIPN20 module to evaluate chemotherapy induced neuropathy in patients treated with chemotoxic medicines Shruti M Velaskar and Sudeep Gupta Tata Memorial Hospital, India
Introduction: Chemotherapy is a main adjuvant treatment in treatment of cancer and majority of chemo toxic drugs are known to produce toxicity. Chemotherapy induced peripheral neuropathy (CIPN) is a potentially severe and a dose limiting side effect. The incidence of peripheral neuropathy varies depending upon the type of chemotherapy and the cumulative dose. Unfortunately it is difficult to accurately estimate and quantify CIPN. CIPN is often documented using the NCI Common Toxicity Criteria; however this instrument is neither sensitive nor sufficiently discriminating in the evaluation of CIPN. There is growing interest in the incorporation of patient reported outcome measures in cancer clinical trials and in the routine care of patients. A number of different patient reported scales have been used to evaluate CIPN. The current version of EORTC QLQ – CIPN 20 module has been validated and tested in several different languages. It has been suggested that QLQ-CIPN20 module may be superior to NCI-CTC in detecting sensory impairment. In order to make use of this module in Indian population this study was undertaken Method: Standard EORTC translation manual procedures were adopted for translation, the module was translated from the original English version into two vernacular languages (Hindi and Marathi) using a “forward-backward” translation procedure and after approval of EORTC translation team the interim version was pilot tested on patients who are treated with chemo toxic drugs and fulfill the eligibility criteria for the study. Informed consent forms were taken from all the patients. The results were documented and approved changes were done in the translated version. Conclusion: Quality of life is extremely important outcome measure in cancer related treatment with systemic therapies. Incidence of peripheral neuropathy was not assessed objectively in previous clinical trials and scoring methods were not effective. EORTC, QLQ is most commonly used QOL questionnaire and is well accepted by patients and reported to cover majority of symptoms following CIPN which are not reported during clinical testing.
Biography Shruti M Velaskar has passed her degree in Occupational Therapy from Seth G. S. Medical College and K. E. M. Hospital, Mumbai University. She is working since more than 15 years in this field and is attached to Tata Memorial Hospital since last 12 years as a Senior Occupational Therapist and is actively involved in cancer related clinical research and publication. She was awarded Fellowship for attending 2nd EORTC, QOL symposium held at Brussels, Belgium. She was awarded with “Best Scientific Paper” “Kamala V Nimbkar trophy for research and publication during 45th AIOTA Conference.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 69 Sushmita Pathy, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Role of radiation in multidisciplinary management of rectal cancer Sushmita Pathy All India Institute of Medical Sciences, India
orldwide colorectal cancer is the fourth most common cancer. Management of cancer rectum has undergone dramatic Wchanges in the last two decades. Recent trials indicate that a multimodality management approach in rectal cancers will improve outcome than surgery alone. Surgery is the gold standard for primary treatment modality. Despite curative resections a significant proportion of patients develop local recurrence. High local recurrence has led to explore the benefit of postoperative radiotherapy. Patients are selected for adjuvant therapy on the basis of high risk histopathological criteria. Neoadjuvant therapy is associated with tumor downstage, improved respectability and better sphincter preservation options in distal rectal cancers. Studies have demonstrated improvement in both local control and overall survival which has led to a significant impact on current management of rectal cancers. Given the dismal survival rates even with reduced local failure after adjuvant radiotherapy role of chemo radiotherapy in the adjuvant setting was evaluated. The optimum sequence of neoadjuvant modalities and adjuvant chemotherapy has been addressed by various randomised trials. Both short coarse radiotherapy and long coarse chemo radiotherapy are logical treatment options. Advances in radiotherapy techniques are beneficial in sparing surrounding normal tissue and deliver o radiation conforming to the target.
Biography Sushmita Pathy is Additional Professor in the Department of Radiation Oncology at Institute Rotary Cancer Hospital at All India Institute of Medical Sciences. She has specific expertise in Gynaeoncology, Gastrointestinal Cancers, Ocular Oncology and Lung Cancer. She has been awarded the prestigious UICC (2001, 2011) and International Agency for Research in Cancer, Lyon (2011) Fellowship. She is also a member of several national and international organizations. Her academic credit includes publications in national and international scientific journals and as reviewer in various scientific journals and UICC panel. She is also actively involved in designing protocols in GI cancers at IRCH. Her research areas include image guided brachtherapy and impact of treatment time in carcinoma cervix, molecular studies in rectal cancers. She has keen interest in Children’s Palliative care and established Paediatric Palliative Care Clinic at IRCH.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 70 Bhaskara Naik S, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Microwave imaging for breast cancer screening -A potential approach Bhaskara Naik S Society for Applied Microwave Electronic Engineering and Research (SAMEER), India
reast cancer is the MOST COMMON CANCER in women all over India and accounts for 25% to 31% of all cancers in Bwomen in Indian cities. We are witnessing an AGE SHIFT, and the average age of developing breast cancer has shifted from 50 - 70 years to 30 - 50 years; and cancers in the young tend to be more aggressive. According to GLOBOCAN (WHO), for the year 2012, an estimated 70218 women died in India due to breast cancer, more than any other country in the world (second: China - 47984 deaths and third: US - 43909 deaths ). Notice the difference in numbers. Digital mammography is considered as the gold standard in the evaluation of breast cancer. Apart from this, ultrasound examination, magnetic resonance imaging and microwave imaging techniques are being offered as the alternative options. This paper concentrates mainly on the evaluation of microwave imaging techniques in the screening and diagnosis of breast cancer and its potential in using it as alternative for mammography are discussed. This paper gives the insight in to current developments in microwave imaging as applied towards breast cancer screening and its future challenges. This report gives an overview of the modalities used in the field of breast imaging based on relevant literatures. Review of the literature shows none of the technology has replaced mammography. Microwave Imaging is one of the prominent technology that can able to eliminate draw backs of mammography and other screening methodologies. Especially It can able to detect tumors in patients of the lower ages which is real concern for Asian countries where mammography fails largely. The emerging ultra wide band microwave (UWB) imaging and microwave tomography can give better result with the advantages of comfortable, low cost, high sensitivity and specificity, more functional information, No X-ray, No health risks, Non invasive, No breast compression hence very simple to perform, sensitive to tumors ,specific to malignancies etc. Different modalities of microwave imaging like, passive, active and hybrid microwave imaging are discussed in this paper.
Biography Bhaskara Naik S , born in Kundapur, India, in 1986. He received his B.E. degree in Electronics and Communication Engineering from MCE Hassan, India in 2008,and currently pursuing MTech degree in RF and Microwave Engineering from IIT Kharagpur, India, Presently he is working as scientist in SAMEER IIT Powai campus Mumbai. His areas of interest are Microwave Imaging, Micro strip antennas and circuits.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 71 Track 3 Day 3 September 17, 2014 3: Anti-Cancer Drug Discovery
Session Chair Session Co-Chair Sharad R Khandelawal Rama Krishna Kancha Institute of Life Science, India Osmania University, India Session Introduction Title: Nanoparticle-assisted drug delivery against cancer: A Review Sharad R Khandelawal, Institute of Life Science, India Title: Complementary and alternative medicinal use of vechur cow urine in cyclophosphamide induced immunosuppressed mouse model K T Naseema, College of Veterinary and Animal Sciences, India Title: A facile synthesis of 2H-indazoles under neat conditions and further transformation in to aza-γ-carboline alkaloid analogues in a tandem one-pot fashion Duddu S Sharada, Indian Institute of Technology, India Title: Targeting oncoprotein stability: HSP90 inhibitors as potential chemotherapeutics to overcome cancer drug resistance Rama Krishna Kancha, Osmania University, India Title: Body image and sexual problem in young breast cancer patients in south indian population Ajit Singh, Manipal University, India Sharad Khandelwal et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Nanoparticle-assisted drug delivery against cancer: A review Sharad Khandelwal and Swati Bhavsar Institute of Life Science, India
anoparticles have been extensively used for drug delivery in cancer therapy. A trimeric complex of mononclonal antibody- Nnanoparticle-anticancer drug increases the specificity of the drug attack onto the cells which have forgotten to die. This composite has not only been effective in therapy but also in the cancer diagnostics purpose. There are several factors affecting the pharmacokinetics and the pharmacodynamics of the drug which ultimately affect the journey of the drug, the penetration, the entry of the drug in the cancer cell and the final dosage that ultimately reaches the target. The challenge lies in reducing the drug action on the non cancerous cells thereby reducing the side effects of the cancer therapy. This review article overviews several studies and the outcomes related to the use of nanoparticles in the antibody guided cancer therapy for mounting the drug specificity. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 74 K T Naseema et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Complementary and alternative medicinal use of vechur cow urine in cyclophosphamide induced immunosuppressed mouse model K T Naseema, Usha P T A, Rani S S, Mini B, Priya P M and Muhammed E M College of Veterinary and Animal Sciences, India
echur cattle (Bos indicus), is the smallest breed of cattle originated in the hot and humid southern part of Indian peninsula. VVechur cow urine has been traditionally used as a complementary and alternative medicine for immunomodulation in immunodeficiency diseases and to reduce the side effects of cancer or cancer chemotherapy. But scientifically conducted analysis or animal studies have not been performed yet. In the present study, the immunomodulatory effects of Vechur cow urine was investigated in normal as well as immunosuppressed mouse model and compared with that of crossbred cow (Bos indicus×Bos taurus) urine. The modulating effect was evaluated on humoral and cell mediated immune response using Swiss- albino mice. The cow urine distillate was administered orally at the dose rate of 10.8 ml/kg body weight for 19 days. Immune system was suppressed by intraperitoneal administration of cyclophosphamide at the dose rate of 30 mg/kg body weight. The Vechur cow urine showed pronounced immuno protective activity by significantly (p≤0.05) increasing the total leukocyte count, lymphocyte count, HA titre, number of antibody producing cells, BMC (bone marrow cellularity) and DTH (delayed type hypersensitivity) responses in both normal and immunosuppressed mice and this effect was superior when compared to crossbred cow urine. The results indicate that Vechur cow urine significantly reduced the cyclophosphamide induced immunosuppression by stimulating both cellular and humoral immunity which need further investigation to validate the results clinically and to make use of the Vechur cow urine in cancer treatment and in immunodeficiency diseases such as AIDS. Hence, we demonstrate the synergy of Vechur cow urine with chemotherapy in alleviating the side effects such as deregulated apoptosis and immunosuppression. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 75 Duddu S Sharada et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
A facile synthesis of 2H-indazoles under neat conditions and further transformation into aza-γ- carboline alkaloid analogues in a tandem one-pot fashion Duddu S Sharada, Shinde Vidyacharan and Arepally Sagar Indian Institute of Technology Hyderabad, India
eterocycles are widely distributed in natural compounds and have vast applications. Among them, nitrogen-containing Hheterocycles play a key role as alkaloids in plant kingdom and have biological significance. Thus, there is a need for developing facile, efficient and nonpolluting synthetic procedures to build novel heterocycles reducing the use of organic solvents and toxic reagents. Nowadays every synthetic chemist is finding a way to develop reaction in greener way. Indazoles being N-heterocycles are gaining a lot of importance in the field of medicinal and organic chemistry as they exhibit a broad spectrum of pharmacological and biological activities. 2H-indazoles are widely used in pharmacy sector than 1H-indazoles due to their potent bioactivities like anti-tumor, anti-microbial, anti-inflammatory, HIV protease inhibition etc. For example, drugs like MK-4827 (anticancer) and pazopanib (tyrosine kinase inhibitor), incorporate this basic scaffold. A number of synthetic methods have been reported in the literature to build indazole scaffolds, however, selective synthesis of 2H-indazoles is difficult. Hence, considering the potent bioactivities of compounds possessing a 2H-indazole core and in continuation of our interest in developing novel heterocyclic compounds under catalyst-free and solvent-free conditions (CFR & SFR), herein, for the first time a facile and green protocol has been developed for the synthesis of 2H-indazoles. The key features of this methodology are operational simplicity, no purifications, excellent product yields and environmental friendliness. We further developed an expedient one-pot protocol for C-C bond formation at C-3 position of indazole via Pictet-Spengler strategy leading to Indazolo quinoxaline from arylazide. Thus, this CFR & SFR, one-pot methodology should prove useful for facile synthesis of such scaffolds on industrial scale.
Biography The primary research interest of Dr. D. S. Sharada involves development of new synthetic methodologies, with main focus on multicomponent reactions (MCRs) for the expedient creation of chemical libraries of drug-like compounds with complexity and diversity. She is also involved in developing new and environmentally compatible methods for the formation of C-C and C-heteroatom bonds through Cross-Dehydrogenating-Coupling (CDC) strategies. At present she is guiding six PhD students.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 76 Rama Krishna, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Targeting oncoprotein stability: HSP90 Inhibitors as potential chemotherapeutics to overcome cancer drug resistance Rama Krishna Kancha Osmania University, India
dentification of mutated tyrosine kinases as underlying genetic events in the pathogenesis of several cancer types led to Ithe development of chemotherapeutics that target their activity. The successful use of imatinib (Gleevec or Glivec) in the treatment of chronic myeloid leukemica (CML) has revolutionized the field of targeted cancer therapy. However, the emergence of secondary drug resistance upon targeted treatment has posed significant clinical challenge in multiple cancer types. For example, point mutations in the kinase domain that abrogate inhibitor binding were reported in EGFR (non-small cell lung cancer, NSCLC), ERBB2 (breast cancer), ALK (neuroblastoma), c-KIT (gastroinstesinal stromal tumors, GIST) and FLT3 (acute myeloid leukemia, AML) kinases. Thus, there is an urgent need to identify alternate treatment strategies to effectively treat cancer as well as to prevent the emergence to secondary drug resistance. It is important to note that several oncoproteins, especially mutated kinases were shown to be HSP90 clients i.e., these non-native versions of the protein bind to and are stabilized by the HSP90 chaperone. It has been shown previously that the inhibition of HSP90 activity by specific inhibitors lead to the destabilization and as a consequence degradation of the HSP90 client oncoproteins. However, since many house- keeping proteins inside the cell are also stabilized by the HSP90 chaperone, it is uncertain if selective toxicity against cancer cells versus healthy cells can be achieved. To test this hypothesis, we established a panel of isogenic cell lines that stably express FLT3-ITD mutation with wild-type or drug-resistant mutant kinase domain. Biochemical analysis revealed that all the FLT3 mutants tested bind to HSP90 and were degraded upon HSP90 inhibitor treatment. Importantly, HSP90 inhibitors induced dose-dependent toxicity selectively in cells that were transformed by FLT3 mutants. Even though HSP90 inhibitors showed non-specific toxic effects on non-transformed (wild-type) cells, a significant therapeutic window was achieved at certain inhibitor concentrations. Interestingly, a combination of FLT3 kinase inhibitor and HSP90 inhibitor abrogated the emergence of secondary drug resistance in a cell-based screening assay. Thus, these pre-clinical results indicate towards the possibility of the usage of HSP90 inhibitors to target FLT3-mutant AML either alone or in combination with kinase inhibitors. Furthermore, these results encourage for the development of novel HSP90 inhibitors with enhanced efficacy to selectively target cancer cells. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 77 Ajit Singh et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Body image and sexual problem in young breast cancer patients in South Indian population Ajit Singh1, Rajat Rana2 and S Dilip Kumar2 1Manipal University, India 2Annamalai University, India
Purpose: The purpose of this study was to determine the frequency of body image and sexual problems after 12 month of follow up among women diagnosed with breast cancer at age 35 or younger. Background: Types of breast cancer treatment effect physical appearance as loss of the body part, disfigurement, scars or skin changes. The goal of this paper is to comprehend the body image and sexual distress of newly diagnosed younger breast cancer survivors. Methods: A multi-ethnic population-based sample of 72 out of 124 women aged 21–35 who were married or in a stable unmarried relationship were interviewed with in situ, local, or regional breast cancer. The women participating in this study were underwent treatment from 2003 to 2013 at 2 different hospitals located in south India. Results: Body image and sexual problems were experienced by a substantial proportion of women after diagnosis or treatment. Different type of treatment patterns were used as 59 (81.94%) women underwent surgery, 39 (54.1%) were treated with CMF chemotherapy, 54 (72.2%) women underwent hormonal therapy and remaining with radiotherapy. The Hopwood Body Image Scale was used for the assessment of the body image perception which shown less physically attraction in most of the patients with self-consciousness, seeing themselves naked in mirror and dissatisfied with scars on their body. The Female Sexual Distress Scale (FSDS) was used to assess the sexual distress in women with breast cancer. The mean score was 24.4 (47%) which relatively shows higher sexual distress with the major sexual problem; distress about sex life, frustration by the sexual problems, dissatisfaction with sex life and inferiority because of sexual problem among the women. Conclusions: Difficulties related to body image and sexuality was common and occurred soon after surgical and adjuvant treatment. Addressing these problems is essential to improve the quality of life of young women with breast cancer.
Biography Ajit Singh is Research Fellow in Dept. of Pharmacy in Manipal College of Pharmaceutical Sciences. He is expertise in Pharmaceutical Care, Drug information, ADR reporting. He has also hands-on experience in Data mining (MEDLINE, MICROMEDEX), Clinical regulatory guidelines (ICH GCP, ICMR, CSDCO), Software tools (Winnonlin and VigiFlow).
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 78 Track 4 Day 3 September 17, 2014 4: Clinical Oncology
Session Chair Session Co-Chair Sharad R Khandelawal Rama Krishna Kancha Institute of Life Science, India Osmania University, India Session Introduction Title: Role of diagnostic laparoscopy and CA125 levels in detecting peritoneal metastasis in gastric carcinoma: A comparison with contrast enhanced computed tomography staging Hemant Kumar Singh, JIPMER, India Title: Breast cancer screening using computational approaches Mahua Bhattacharya, ABV Indian Institute of Information Technology & Management, India Title: Lung cancers – prevention and management through exercise interventions Manikonda Prakash Rao, International and Constitutional Laws, India Title: Need and tolerance of G-CSF in patients with targeted CD20+ diffuse large B-Cell lymphoma treated with R-CHOP regimens Chinmoy K Bose, NCRI, India Hemant K S et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Role of diagnostic laparoscopy and CA125 levels in detecting peritoneal metastasis in gastric carcinoma: A comparison with contrast enhanced computed tomography staging Hemant K S, Sreenath G S, Verma and Ramesh Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), India
Background: Contrast enhanced computed tomography (CECT) is a reliable investigation to identify local infiltration and operability in gastric carcinoma. However, its accuracy in detecting peritoneal metastasis is contentious. This is because, peritoneal metastases have been found on explorative laparotomy in patients with a negative CECT result. In such patients, diagnostic laparoscopy and estimation of blood levels of CA125 antigen may be useful adjuncts to CECT in detecting peritoneal metastasis and avoiding morbidity associated with explorative laparotomy. Aim: To compare the sensitivity of diagnostic laparoscopy and blood levels of CA 125 with CECT in detecting peritoneal metastasis in gastric carcinoma. Materials and Methods: This was a prospective study. Thirty five patients with gastric carcinoma (proven by endoscopy and biopsy) but with no detectable peritoneal metastasis by CECT were included. All of them underwent diagnostic laparoscopy and analysis of peritoneal free fluid for malignant cells. In all these patients, serum of CA-125 antigen was estimated using chemiluminescence. CA-125 levels >35 IU/L were taken as suggestive of peritoneal metastasis. Results: Diagnostic laparoscopy detected peritoneal metastasis in 10 patients (28%) with no detectable metastasis by CECT (p=0.0006). Seven of these patients also had surface liver secondaries (p=0.0027). 80% of the patients with peritoneal metastasis detected by diagnostic laparoscopy had elevated CA-125 levels (p=0.0534). Conclusion: Diagnostic laparoscopy is superior to CECT in detecting peritoneal metastasis. Blood levels of CA-125 antigen can help in selecting patients who are likely to have peritoneal metastasis by diagnostic laparoscopy. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 80 Mahua Bhattacharya, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Breast cancer screening using computational approaches Mahua Bhattacharya ABV Indian Institute of Information Technology & Management, India
reast cancer is a significant public health problem for women throughout the world. Women have better chance to survive Bif breast cancer can be detected early. The medical practitioners use different imaging sensors for detection of breast cancer like X-ray mammography, ultrasonography (USG), magnetic resonance imaging (MRI), Gamma Ray imaging etc. Among all these different imaging sensors, X-ray mammography has been considered to be one of the most reliable and conventional method for early detection of breast carcinomas. Mammograms are examined when evidences of direct/indirect signs of abnormalities like micro calcifications, skin thickening and masses are observed. However, it is difficult for radiologists to provide accurate and uniform interpretation for the enormous amount of mammograms generated in widespread screening. So they turn to computer assisted diagnosis for an alternative treatment planning. However, poor visibility of mammographic features is due to the minor difference in X-ray attenuation between normal glandular tissues and suspicious region. Thus the improvement of mammographic image contrast is essential for breast cancer screening. To deal with these problems, it is very important to enhance the contrast between the region of interest (ROI) and background, to segment and extract the features of suspected regions (SRs) effectively and hence to classify SR more accurately. Segmentation is designed to find suspicious regions containing masses/micro calcifications and separate the SRs from the background that will be used for extracting features of SRs. In the feature extraction, features of SRs are selected and hence will be classified into benign, malignant groups. It has been observed that micro calcifications appear as clusters of few pixels which corresponds to high frequency components in the image spectrum. These fine and granular spot of micro calcifications may not always be appeared in the segmented results. Using the multi-resolution capability, the wavelet transform could separate small objects (micro calcifications) from large objects (background structures). Finally, micro calcifications may be segmented using straightforward iterative, linear or local thresholding method. Recently hybrid fuzzy logic based segmentation algorithm has been developed to locate the suspicious regions in mammograms to resolve uncertainties inherent in the mammograms. The set of spatial features include: average gray level of the foreground, average gray-level of the background, standard deviation, skewness, uniformity, entropy of the gray-level of the region of interests and the contrast. A statistical method examining texture is the gray-level co-occurrence matrix. When the expert knowledge is not explicitly defined or cannot be represented in terms of statistically independent rules, ANF may provide a better solution than expert systems, and it can efficiently learn nonlinear mappings through examples contained in a training set, and conduct complex decision making. Finally, ANF can be effectively updated to learn new features. Experimental results show that the neural network classifier has better performance than the radiologists in term of the area under the receiver operating characteristics (ROC) curve. Although many previously proposed approaches have led to impressive results, several fundamental issues remain unresolved in the application of computer assisted systems. The major reasons are poor contrast of mammograms; problem to segment micro calcifications and localized masses appeared in the mammograms and the problem to resolve the impreciseness/vagueness of significant features. Nevertheless, designing better feature detection and feature selection still remain a challenge for such system. Therefore, there is still scope for improving the detection rate of masses/micro calcifications in computer assisted screening process of mammogram.
Biography Mahua Bhattacharya is an Associate Professor since December 2006 of ABV Indian Institute of Information Technology and Management, an MHRD Institute of Govt. of India. She got her BTech and MTech degree from the Institute of Radio Physics and Electronics, University Of Calcutta. She worked as a Research Scientist at Indian Statistical Institute, Calcutta from 1995 till 2000 and got her PhD degree on Medical Image Processing in 2001. Her area of specialization is based on Image Processing, Pattern Recognition, Computer Vision, and Soft Computing. She has published more than 120 papers in international journals and conference proceedings and as book chapters. She is a selected member of Irish Pattern Recognition and Classification Society, 2006, UK and member of International Association of Pattern recognition (IAPR) and coordinating member of National Brain Research Centre (NBRC). She is invited speakers in different international and national forums and serves as Program Chairs, Session Chairs and Advisory Technical Committees of International Conferences. She is reviewers of IEEE, Elsevier, Springer and Wiley journals. She is also acting as Principal Investigator of various Govt. sponsored research projects.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 81 Manikonda Prakash Rao, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Lung cancers: Prevention and management through exercise interventions Manikonda Prakash Rao International and Constitutional Laws, India
Background: The objective of the paper is to create awareness among people about alternative and complimentary methods to protect themselves from pathological changes in Lung Tissues which may lead to Lung Carcinomas. The following changes take place in airways as a result of Lung diseases 1) Inflammation 2) Hyper secretion of mucus: Is the result of goblet cell hyperplasia in respiratory mucosa and is a prominent feature of inflammation. It is a major pathological feature of diseases. Chronic mucus hyper secretion is a potential risk factor for an accelerated loss of lung function. It is a common feature in elderly. The thick viscous mucus in the Lungs will be conducive to pathogens. Continued inflammation and mucus hyper secretion may significantly contribute to Lung Lesions leading to carcinomas in the airway. 3) Bronchospasm Chronic mucus hyper secretion is a potential risk factor for an accelerated loss of lung function. It increases risk of hospital admission as a result of lower respiratory tract infections. Methods: Exercise is a potent medication in history. They are mucokineses and a recipe for healthy ageing. Exercises strengthen the remodeled airways and reset the biological ageing process. They are a) Upper airway passages cleansing Exercises: They help in cleansing mouth, nose and pharynx, the primary sites of colonization of pathogens and the sinuses, the way stations to the brain. These exercises should be practiced with hypertonic solution i.e., a solution having greater osmotic pressure than that of cells or body fluids and draws water out of cells thus inducing plasmolysis. b) Bronchial airways cleaning exercises: They are based on forced expiratory techniques. They help in draining out excess mucus from bronchial airways. c) Physical, aerobic and yogic exercises: help in strengthening The Inspiratory and expiratory muscles. Conclusions: Any mucus related respiratory health problem commences from upper airway passages and spreads to trachea bronchial tree as they constitute only one path way. The mucociliary clearance mechanism becomes defunct when excess and sticky mucus forms. Once the upper airway passages are cleaned of it, the defunct cilia become active and ciliate mucus towards nasal passages and it can be blown out easily. The bronchial airways cleaning exercises help in draining out total mucus from airways. The respiratory and other diseases originating from its pathway come under control. Healthy ageing process commences. The exercises are based on the concept “Once the offending factor, excess mucus is removed, the origin of it, Inflammation gets resolved “There will be no scope for formation of lesions leading to carcinomas in the Lungs and if already lesions are formed, treating them will become easy. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 82 Chinmoy K Bose, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Need and tolerance of G-CSF in patients with targeted CD20+ diffuse large B-cell lymphoma treated with R-CHOP regimens Chinmoy K Bose NCRI, India
Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin lymphoma (NHL) and is commonest in India. Targeting CD20+ cells by rituximab is therapy of choice now (R-CHOP). We face dreadful complication of febrile neutropenia which is treated by new GM-CSF, Pegfilgarstim. However in DLBCL it may improve CD20 expression also probably by activating effectors. Aim: This study was undertaken to evaluate the tolerability of Pegfilgarstim. We also studied efficacy of Pegfilgarstim in terms of prevention of neutropenia and more importantly better response rate. Methods: A total of fifty-one patients below and above 60 years with newly diagnosed DLBCL were treated with R-CHOP every 21 days for 6–8 cycles and Pegfilgarstim 250 μg/m2 per day on day 4 in NCRI from Jan 12 to Jan 14. Twenty-eight patients were enrolled in >60 yrs with a median age of 72 years (192 doses) and 23 patients in <60 yr age group with Median age 37 yrs (176 doses). Patients were evaluated for response after cycles 4, 6, and 8. The primary endpoint was the rate of complete response, and secondary endpoints were progression-free survival (PFS), event-free survival, and overall survival (OS). Results: Tolerability was same in both the groups. Side effects were mainly bone pain/body ache (5.2 vs. 5.1%) and local rash in some cases. A complete response (CR) was achieved in 10 (35.7 %) of elderly patients and 9 (39%) in younger group. After a median follow-up of 19 months, the 2-year PFS and OS were 78% (n=21) and 85% (n=24) in elderly and 87% (n=20) & 91% (n=21) in younger group. Conclusions: These data suggest that survival outcomes may be modestly improved when pegfilgarstim is combined with R-CHOP in the treatment of elderly DLBCL. Pegfilgarstim was well tolerated. Further investigation of Pegfilgarstim in combination with rituximab-containing chemotherapy is warranted. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 83 207th OMICS Group Conference Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Young Researchers Forum
GCC-2014 Page 85 Young Researchers Forum Day 3 September 17, 2014 Session Introduction Title: Monodisperse magnetic nanoparticles as an efficient MRI contrast agents for cancer imaging Deepika Sharma, Institute of Nano Science and Technology Habitat Centre, India Title: Small molecule modifiers of microRNA - in search of new therapeutics for cancer Debasmita Mukhopadhyay, Indian Institute of Chemical Technology, India Title: In silico profiling of single nucleotide polymorphisms in [EZH] 2 gene and their involvement in cancer progression Richa Vasan, VIT University, India Title: Effect of NDMA in the yeastO6-AGT (O6-alkylguanine-DNA alkyltransferase) gene S Ashwini Devi, VIT University, India Title: Drugs for epimutation obtained from natural products in-silico drug design Lekshmi Mohan, VIT University, India Title: An energy efficient scientific framework for the establishment of healthy pathways Syed Tazib Rehman, Sri Chaitanya College, India Title: Strong systemic and mucosal immune responses to surface modified PLGA microparticles containing HPV antigen administered intranasally D Krishna Kumar, Erode College of Pharmacy, India Title: Study of antioxidant vitamins, prostate specific antigen and role of insulin resistance in prostate cancer M Prasad Naidu, Narayana Medical College, India Title: Anticancer potential of Euphorbia neriifolia leaves and isolated flavonoid against N-nitrosodiethylamine-induced hepatocarcinoma in mice Pracheta Janmeda, Banasthali University, India Title: Alternative cancer cures: Facts or myths? Akhila Dandamudi, Vignan University, India Title: Combinatorial association of liver specific vehicular system and tumor dependent expression of dsRNA inducing histone and DNA methylation of c-Myc P2 promoter in hepatocellular carcinoma cells Mohammad Khalid Zakaria, All India Institute of Medical Sciences, India Title: Statistical analysis of lung cancer in India Prasad Balachandran, Sri Ramakrishna Engineering College, India Deepika Sharma, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Monodisperse magnetic nanoparticles as an efficient MRI contrast agents for cancer imaging Deepika Sharma Institute of Nanoscience and Technology, India
espite of technical advances in many areas of diagnostic radiology, the detection and imaging of human cancer remains Dpoor. In pursuit of this, the role of magnetic nanoparticle architecture has been poorly investigated. Magnetic nanoparticles composed of maghemite cores coated with stevioside were synthesized through simple co-precipitation method. Co- precipitation reaction without stevioside was also carried out as a control.We obtained stable stevioside coated nanostructures ranging from 10 nm to 100 nm. In this study, further long term MRI detection of tumour cells can be achieved due to facile and non toxic cell uptake of these iron oxide nanostructures. Our main focus is to generate the nanoparticle with cooperative magnetic behaviour and highly crystalline maghemite core which will in turn enhance contrast on T2 weighted MR images, while prevailing biocompatibility. If a contrast agent can someday be targeted to a living cancer cell anywhere in the body, then a cytotoxic agent can be targeted as well. In fact, the smaller the detected tumour, the more options will be available to kill it. We will further analyse the physics and chemistry of cancer imaging and highlight the fundamental principles underlying the detection of malignant cells within a background of normal cells.
Biography Deepika Sharma is DBT Research Associate at Institute of Nanoscience and Technology. Her research interest lies at the interface of engineering, medicine and biology to develop novel platforms for understanding, diagnosing and treating human disease. Specifically, her work is focused on diagnostics and treatments for cancer and is centred on designing and development of targeted nanoparticles to perform complex task such as multimodal, non-invasive tumour imaging; trigger the release of a targeted, therapeutic payload and multifunctional agents for cancer therapies. She has published in reputed journals like Biotechnology Advances and Trends in Biotechnology.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 87 Debasmita Mukhopadhyay et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Small molecule modifiers of microRNA: In search of new therapeutics for cancer Debasmita Mukhopadhyay, Nishant Jain, S Chandrasekhar and Manika Pal Bhadra Indian Institute of Chemical Technology, India
icro RNA are endogenous small non coding RNA with 20-22 nucleotide long that are transcribed from the chromosomal MDNA. They exhibit their effect after getting partially attached to the cogent mRNA of a particular gene. Although there are numerous evidences which established that miRNa behave as onco genes as well as tumour suppressors, however there is lack of evidence in the role of miRNa on tumour metastasis. Here, it is shown anaza-flavanones group of compound containing an unnatural amino acid that negatively regulates mir-10b activity. MiR10b is predominantly expressed in metastatic breast cancer cell line, Pharmacological inhibitor of miR10b resulting in reducing tumour invasion and metastasis of breast carcinoma in vitro. Initially it was analysed for mir-10b levels in transfected mir-10b luciferase reporter gene construct in MDAMB-231 cell line in the presence of AZT-DMAD. It was observed that the cells treated with this compound have remarkably lower level of mir-10b using dual luciferase assay system. Further we checked the expression of different Epithetical – mesenchymal marker both in treated and untreated condition since EMT play an essential role in cancer metastasis. Notably inhibition of miR 10b expression by AZT-DMAD consequently reduces the expression of cell proliferation marker. Interestingly, over expression of miR10b in breast cancer cell line, exhibit very high level of angiogenesis and formation of new vasculature. It was shown decreased miR10b activity in cells treated with AZT-DMAD lowered angiogenesis. Expression of mir10b is induced by the transcriptional factor Twist1 which directly bind to the promoter of this miRNa. Hence it was tried to find out the expression of TWIST1 after treatment with this compound and surprisingly found that mir10b inhibition leads to TWIST1 down regulation as well as the pro metastatic gene RHOC and up regulation of HoxD10. These finding suggest that the aza Flavanonones specifically targets mir-10b by modulating its upstream transcriptional factor, which in turn reduces EMT marker, cell proliferation and decently inhibits the pro-metastatic gene, leading to reducing tumour cell invasion and metastasis.
Biography Debasmita Mukhopadhyay is pursuing her PhD from Indian Institute of Chemical Technology, Hyderabad. She has been awarded as ICMR-SRF in the year 2013. She has published 5 papers in reputed international journals.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 88 Richa Vasan et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
In silico profiling of single nucleotide polymorphisms in EZH2 gene and their involvement in cancer progression Richa Vasan, Manjari Trivedi, Sulekha Nair, Divanshu Gupta, Lekshmi Mohan and Trupti N V Patel VIT University, India
nhancer of Zeste Homolog 2 or EZH2 is an enzyme that plays an active role in transcriptional repression of several Egenes over successive cell generations, especially during embryonic cell development and cellular differentiation. The catalytic subunit of human polycomb repressive complex 2, EZH2 acts by tri-methylating lysine 27 of histone 3 protein on DNA. EZH2 is also known to act as the scaffolding protein for the action of DNA methyltransferases, which further helps in chromatin condensation and gene silencing. EZH2 is over-expressed and is a major biomarker for cancers of prostate, breast, brain and other cancer progressions, including those of the bladder, gastric, liver and blood (leukemia). The most important contribution is that this overexpression leads to silencing of the major tumor-suppressor genes through increased levels of histone methylation in the promoter regions of these genes. In the present study we aim to retrieve the known mutations in EZH2 (single nucleotide polymorphisms-SNPs) from the COSMIC database and look at the severity of each mutation on the functionality of the enzyme using multiple in silico approaches including Molecular Dynamics Simulation.
Biography Richa Vasan is in her 5th year of MSc Integrated Biotechnology at VIT Vellore-632014, Tamil Nadu. She has worked on various research projects during the past 3 years and is working on the foresaid project since last 6 months.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 89 S Ashwini Devi et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Effect of NDMA in the yeast O6-AGT (O6-alkylguanine-DNA alkyltransferase) gene S Ashwini Devi, M Fahmina Yasmin, Madhukiran, Mankad Bhavik, Komal and N V Patel Trupti VIT University, India
itroso compound are known carcinogens with an effect of A: T to G: C transitions on DNA. O6-AGT (O6-alkylguanine- NDNA alkyltransferase) is a yeast homologue of human MGMT (O6-methylguanine DNA methyltransferase) and is an important enzyme which helps in removal of NDMA formed adducts, thus maintaining the genome integrity. However, alterations in the very gene may lead to accumulation of mutations that may be induced by N-nitroso compounds and thus contribute to the genomic instability. These characteristics combined with the other epigenetic factors may contribute to tumorigenesis. In the present study, we treat Saccharomyces cerevisiae with NDMA (N-nitrosodimethylamine) and check the uptake of the same by HPLC. We also study the gene O6-AGT (O6-alkylguanine-DNA alkyltransferase) for any induced mutations by this nitroso compound. These results showed that NDMA was not metabolized by yeast and hence there were no prominent molecular consequences observed.
Biography S Ashwini Devi, pursuing 3rd year of MSc Integrated Biotechnology at VIT University, Vellore, Tamil Nadu, India. She has worked on various research projects during the past 2 years and is working on the foresaid project since last 6 months.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 90 Lekshmi Mohan et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Drugs for epimutation obtained from natural products In silico drug design Lekshmi Mohan, Divanshu Gupta, Manjari Trivedi, Richa Vasan, Jay Patel, Trupti N Patel and Naveed A VIT University, India
rognostication of cancer can be advanced by certain epimutational events. Gene silencing caused by the ectopic methylation Pin tumour suppressor genes is one such event. The concatenation of DNA methylation is a series of demethylation, de novo methylation and maintenance of methylation. One of the promising treatments of cancer is to inhibit the enzyme responsible for DNA maintenance. This enzyme is DNA methyltransferase 1 (DNMT1). The interminable activity of this enzyme is required to maintain the framework of epimutation. In this study, the crystal structure of the enzyme has been used to develop non-nucleoside DNMT1 inhibitors using virtual screening (VS), absorption, distribution, metabolism, elimination/ toxicology analysis and molecular docking studies. To create a subset of lead-like natural products, VS was done on 48,531 natural products. Out of all, three of them were found to interact with the catalytic site of DNMT1 (Cys 1226) through the formation of hydrogen bonds. Thus, from this study some potential lead compounds have been identified for the treatment of epimutation.
Biography Lekshmi Mohan is in her 4th year of BTech in Biotechnology at VIT Vellore, Tamil Nadu, India. She has been working in the area of cancer biology from the past three years and is working on the foresaid project since the last six months.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 91 Syed Tazib Rahaman, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
An energy efficient scientific framework for the establishment of healthy pathways Syed Tazib Rahaman Sri Chaitanya College, India
nvironment is the ultimate creation which is created by Almighty without which “Life is Impossible on Earth”. Human Ehealth is being spoiled due to human beings themselves as they are destroying the environment for their temporary desires. One of the ways of protecting health is by detoxifying roads as it contains PAH contaminations (PAHc), which are present in the seal coats of bitumen and coal tar. PAHc are toxic, carcinogenic, mutagenic and even does not spare a pregnant women. PAHc move from a seal coat to our houses by mechanisms like storm runoff, adhesion to tires, wind, foot traffic and votallization. In this paper an idea is proposed to have Healthy Pathways as alternative seal coat with clay by heating it with the help of nuclear energy. We can insert micro nuclear reactor into the road roller. We can use clay as a seal coat as the absorption capacity of the clay depends on the state of hydration and is ranged from 24% to 30.4% water content , clay has a vitrification point below 1100°C (2000°F) . So, this means clay has long-lasting effect. Moreover clay is non-toxic, eco-friendly as well as biodegradable and inexpensive compared to coal tar/bitumen. We can add alluminium silicates before heating, to provide the permanent load baring capacity to the clay roads. Due to large amount of heat production in to the environment during heating with micro nuclear reactor we can use peltier cooler which helps in cooling up the escaped heat. Thus by this design, we can utilize science and technology as boon but not as a bane. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 92 Krishnakumar D et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Strong systemic and mucosal immune responses to surface modified PLGA microparticles containing HPV antigen administered intranasally Krishnakumar D and Ganesan V The Erode College of Pharmacy, India
ervical cancer in India is the second most frequent cancer in women and third most common cancer among women Cworldwide. Human Papilloma Virus (HPV) is a cause of cervical cancer and other anogenital cancers. The currently available prophylactic vaccines for cervical cancer will not provide complete protection against all HPV types. Moreover, the available vaccines are administered via parenteral route and having poor patient compliance. Nasal delivery is a promising method for vaccine administration to give better immunogenicity and patient compliance when compared to conventional parenteral administration. Our objective of the study was to develop a needle free nasal vaccine to prevent the cervical cancer. The HPV antigen loaded PLGA [poly (lactic-co-glycolic acid)] and Glycol Chitosan coated PLGA microparticles were prepared. The prepared microparticles were characterized for its antigen entrapment efficiency, antigen integrity, In vitro release rate, particle size, zeta potential. The immunogenicity of the vaccines was studied with suitable animal models. PLGA microparticles shows negative zeta potential while surface modified microparticles shows higher positive zeta potential. The protein loading efficiency was found more than 80%. Both the coated and uncoated particles exhibited the size range in between 4-10 microns. Surface modified PLGA microparticles shows better immunogenicity as compared to PLGA particles. Surface modified PLGA microparticles proved great potential as a nasal delivery system for infections where systemic and mucosal immune responses are necessary. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 93 M Prasad Naidu et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Study of antioxidant vitamins, prostate specific antigen and role of insulin resistance in prostate cancer M Prasad Naidu, M Krishnamma, S Prasanth Vardhan and J N Naidu Narayana Medical College, India
he incidence of prostate cancer is 5 per 1, 00,000 in southern and eastern Asia. Both genetic and environmental factors Thave been implicated in its etiology. The mitogenic and growth stimulatory effects of Insulin growth factor may be involved in prostate carcinogenesis. To evaluate serum insulin and insulin resistance was estimated by HOMA- IR. Prostatic specific antigen by immuno-enzymatic assay. Vitamins were estimated by high performance liquid chromatography. In our study 30 prostate cancer patients aged 60-80 years were taken as cases. 30 normal age matched disease free person were taken as controls in both groups, Insulin resistance and antioxidant vitamin status was studied. In the present study, the value of HOMA-IR was (p<0.05) is significantly higher compare to controls. Serum vitamin E and vitamin C values for cases was reduced (p<0.05) significantly lower than controls. The development of prostate cancer is a multistep process. Hyperinsulinemia associated with insulin resistance may play a role in pathogenesis of prostate cancer. Prostate cancer cells generate high levels a ROS.
Biography M Prasad Naidu has done MSc in Medical Biochemistry from Narayana Medical College, Nellore affiliated to Dr NTRUHS. He is a Ph.D. Research Scholar from 2013-2014 batch at Dr NTRUHS.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 94 Pracheta Janmeda, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Anticancer potential of Euphorbia neriifolia leaves and isolated flavonoid against N-nitrosodiethylamine- induced hepatocarcinoma in mice Pracheta Janmeda Banasthali University, India
rotective effect of hydro-ethanolic extract of Euphorbia neriifolia leaves and an isolated flavonoid was investigated against PN-Nitrosodiethylamine induced hepatocarcinoma in mice. Experimental mice were pretreated with 150 and 400 mg/kg body wt of EN, 0.5% and 1% mg/kg body wt of butylated hydroxylanisole as a standard antioxidant and 50 mg/kg body wt of ENF for 21 days prior to the administration of a single dose of 50 mg/kg body wt of DENA. Levels of liver markers (AST, ALT & ALP), xenobiotic metabolic enzymes (Cyt P450 and Cyt b5), lipid peroxidation, antioxidants (SOD, CAT, GST and GSH) and other biochemical parameters TP and TC were measured to determine the hepatocarcinoma caused by DENA. DENA administration significantly (p<0.001) decreased the body weight and increased the tissue weight. Activities of liver markers, antioxidants and TP content were significantly decreased (p<0.001), while Cyt P450, Cyt b5, LPO and TC levels were significantly (p<0.001) increased after DENA administration as compared with the normal control group (p<0.001). Pretreatment with EN and ENF counteracted DENA-induced oxidative stress (LPO) and exerted its preventive effects by restoring the levels of liver markers (AST, ALT and ALP), antioxidants (SOD, CAT, GST and GSH) and other biochemical parameters (TP and TC) and xenobiotic enzymes (Cyt P450 and Cyt b5) in liver tissue. In conclusion, the present study showed significant anti-carcinogenic potential of the hydro-ethanolic extract of E. neriifolia and ENF against DENA induced hepatic carcinogenicity. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 95 Akhila Dandamudi, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Alternative cancer cures: Facts or myths? Akhila Dandamudi Vignan University, India
ancer has turned into a nightmare for the health sector in the 21st century. World Health Organization (WHO) has Cofficially declared that, cancer is “the most dangerous killer in the world”. The last century has witnessed a sudden increase in the number of cancer patients with their numbers going up from 1 in 80 in 1990’s to 1 in 3 in the 2000’s. There are many causes for this sudden hike in the number of people fighting with cancer. The drastic changes in the diet, adversary of modernization, the highly precarious lifestyles which we lead and a completely stressed out life are a few that demand to be mentioned. Though a massive amount of research is being carried out in order to devise a cure for cancer, one reliable solution that works is yet to be found. With chemotherapy, radiation or surgery being the norm of the day to treat cancer, it is still feared by due to the radiation/drug-induced toxic side effects. All these have been nudging researchers across the globe to look out for complementary and alternative medicine for the management of cancer. In this pursuit, many medicines have popped up, which, when used in conjunction with other lifestyle changes, claims to prevent or reverse virtually any disease, including cancer. In this review paper, the author would like to enlist the various claims by researchers who proposed alternative cancer cures, which were supposed to have anti-tumor and anti-cancer properties.
Biography Akhila Dandamudi is a graduate in Biotechnology (2013), an independent researcher who is trying to validate the claims made by various people that the complementary and alternative medicines to cure cancer. She has been awarded a Gold Medal for securing the highest marks in her academics in the year 2013. She has presented papers in several conferences.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 96 Mohammad Khalid Zakaria et al., J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Combinatorial association of liver specific vehicular system and tumor dependent expression of dsRNA inducing histone and DNA methylation of c-Myc P2 promoter in hepatocellular carcinoma cells Mohammad Khalid Zakaria1, Imran Khan1, Prashant Mani2, Parthaprasad Chattopadhyay1, Debi P Sarkar2 and Subrata Sinha1,3 1All India Institute of Medical Sciences, India 2University of Delhi, India 3National Brain Research Centre, India
or hepatocellular carcinoma (HCC) therapy, an ideal targeting system could involve a liver specific vehicular system Fcoupled with a therapeutic modality active only under tumorigenic condition. One such liver targeting entity is a reconstituted Sendai viral envelop, known as Sendai virosome, containing the surface fusion (F) proteins which interact with the asialoglycoprotein receptors (ASGPRs) of hepatocytes. Transcriptional gene silencing (TGS), compared to post transcriptional gene silencing (PTGS), is heritable and does not require continuous supply of the effectors si/shRNA molecules, leading to long term transcriptional repression of the target gene. Utilizing such F-virosomal delivery system, HCC specific fusion cassettes of alpha-fetoprotein (AFP) promoter, with different tumour specific enhancers, was used to express shRNA targeting proto-oncogene c-Myc P2 promoter for induction of TGS in neoplastic liver cells. The combinatorial association of Sendai F-virosomes with the AFP promoter/enhancer expression system ensured that the c-Myc TGS inducing shRNA was active only in transformed liver cells. We demonstrated that such c-Myc shRNA expression system was efficient in inducing cell type as well as tumour specific activation of cell death in hepatocarcinoma cells. This was due to the methylation of both histone (H3K9Me2 and H3K27Me3) and CpG islands, with decreased histone 3 acetylation, around the target c-Myc P2 promoter. Moreover, this could serve as an added advantage over other gene therapeutic approaches, since persistent c-Myc inactivation is required for HCC suppression. Additionally, the Sendai F-virosome/AFP promoter/enhancer system could also be used to introduce genes specifically in embryonic liver and to tackle recalcitrant cancer cells with de-regulated c-Myc.
Biography Mohammad Khalid Zakaria has completed his PhD on Cancer Therapeutics from All India Institute of Medical Sciences (A.I.I.M.S), New Delhi in October 2013. He has published in reputed international peer reviewed journals, is a co-author in an international patent and has qualified all national level entrance examinations aiding in financial assistance for PhD tenure. Academically he always has been among the top 2 students of the class, during masters and graduation, and is a good speaker as well. He has also won many journal club and seminar presentation awards.
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 97 Prasad Balachandran, J Cancer Sci Ther 2014, 6:9 http://dx.doi.org/10.4172/1948-5956.S1.037
Global Cancer Conference & Medicare Summit September 15-17, 2014 Hyderabad International Convention Centre, India
Statistical analysis of lung cancer in India Prasad Balachandran Anna University, India
ung cancer in India has broadened in lengths and breadths as a public institution. This paper deals with the statistics Lof prevailing lung cancer estimates, its survivors and the affinity of lung cancer towards Indian nationals’ lifestyle. The estimates are concluded based on direct and indirect inputs from list of hospitals and cancer institutes. The carried inputs were jotted down by SWOT analysis. Thus the lung cancer estimates in India are effectively reproduced. [email protected]
J Cancer Sci Ther 2014 Volume 6, Issue 9 ISSN: 1948-5956, JCST an open access journal GCC-2014 September 15-17, 2014
Page 98